




Office of the Chancellor
 105 Spilman Building | Mail Stop 101 | East Carolina University | Greenville, NC 27858-4353
 252-328-6212 office | 252-328-4155 fax

MEMORANDUM

TO: Matthew S. Brody, Vice President for Human Resources
 University of North Carolina System Office

FROM: Cecil P. Staton, D.Phil., Chancellor
 East Carolina University 

RE: Reclassification of Tier I SAAO Position
 Vice Chancellor for Health Sciences & Dean of the Brody School of Medicine

DATE: December 4, 2018

The purpose of this memorandum is to formally request your approval of the reclassification of a Tier I Senior Academic and Administrative Officer (SAAO) position at East Carolina University: Dean of the Brody School of Medicine and Senior Associate Vice Chancellor, Medical Affairs to become the Vice Chancellor for Health Sciences and Dean of the Brody School of Medicine. This reclassification combines these two positions into one. In support of this request, I have attached a proposed job description and organizational chart. I have also included, below, a proposed salary range for your review and consideration:

Minimum - \$512,828
 Maximum - \$1,025,656
 50th - \$641,035
 75th - \$769,242

In accordance with your request, I have also included the incumbent's CV. The proposed salary action associated with this reclassification will require Review and Consultation by the Board of Governors. The current salary of the Dean is \$600,000, with a \$60,000 stipend for his role as Interim Vice Chancellor for Health Sciences. We are proposing a total salary of \$780,000 associated with this reclassification.

The prior incumbent in the role of Vice Chancellor for Health Sciences, Dr. Phyllis Horns, was earning a salary of \$503,126 when she stepped down from that position effective July 31, 2018. She will be returning to ECU's College of Nursing faculty, and has a PhD in Nursing. At the same time that Dr. Horns was serving as Vice Chancellor for Health Sciences, Dr. Mark Stacy, who has a medical degree, was serving as the Dean of the Brody School of Medicine and Senior Associate Vice Chancellor, Medical Affairs, and was earning a salary of \$600,000. The combined salaries for Dr. Horns and Dr. Stacy totaled \$1,103,126. If Dr. Stacy is paid \$780,000 for this reclassified role, this would represent a salary savings of \$323,126.

I understand that President Spellings will review the reclassification and the Board of Governors will review the proposed salary increase and, if these proposed actions meet with their respective approvals, you will inform us that they have been approved contingent upon the approval by our Board of Trustees of the incumbent in this reclassified position.

I would greatly appreciate your review and consideration of this request as quickly as possible.

Attachments

cc: Kitty H. Wetherington, Associate Vice Chancellor for HR, ECU

Vice Chancellor for Health Sciences and Dean, Brody School of Medicine Position 952603

Minimum Qualifications:

- MD, PhD, DO, or related terminal degree.
- Ten years of experience in leadership roles at an academic health center.
- Demonstrated experience in engaging and working with boards, academic health sciences faculty, deans, and community-based health care leaders.
- Demonstrated success in the implementation of new health care and innovative academic programs.
- Financial leadership for a diverse and financially sound medical faculty practice plan.
- Demonstrated creativity and ability in attracting new sources of revenues (research grants, foundation funding, etc.).
- Successful experience in team building and evidence of visionary leadership.
- Demonstrated commitment to diversity and inclusion and an ability to work with diverse employee and student populations.

Primary Purpose of Organizational Unit:

The East Carolina University Division of Health Sciences is known for the highly skilled and compassionate graduates it produces across the spectrum of health professions. The division is equally renowned for its commitment to serving and improving the health of the citizens of eastern North Carolina. The division is comprised of the following areas:

- College of Nursing
- College of Allied Health Sciences
- School of Dental Medicine
- Brody School of Medicine (11 clinical academic departments, 8 basic science academic departments)
- East Carolina Diabetes & Obesity Institute
- East Carolina Heart Institute
- William Laupus Health Sciences Library
- NC AgroMedicine Institute
- Eastern Area Health Education Center (AHEC)

Primary Purpose of Position:

The Vice Chancellor for Health Sciences and Dean, Brody School of Medicine (BSOM) (Vice Chancellor and Dean), is responsible to the Chancellor for policy, operations, and oversight of academic, clinical, and research programs of the BSOM and the Division of Health Sciences. The Vice Chancellor and Dean holds a tenured academic appointment with senior rank in one of the health sciences departments appropriate to the individual's qualifications. The Vice Chancellor and Dean advises the Chancellor on all matters related to the practice of medicine and the education of physicians, biomedical scientists, and public health professionals.

The Vice Chancellor and Dean represents the Division on University committees such as the Faculty Senate, Graduate Council, Academic Council and Chancellor's Executive Council; and represents the University in health-related academic and administrative groups nationally, regionally and state-wide including professional organizations and accrediting agencies. For instance, the Vice Chancellor and Dean represents the BSOM and/or the Division of Health Sciences in appropriate groups and councils

dealing with plans and policies for medical education on a statewide basis (e.g., UNC System Office, the State of North Carolina Institute of Medicine, the North Carolina Medical Society, and the Area Health Education Center program for the State). At the national level, the Vice Chancellor and Dean represents the BSOM and/or the Division on appropriate committees and councils of the Association of American Medical Colleges, the American Medical Association, and other relevant national organizations and agencies. The Vice Chancellor and Dean also serves as the primary legislative spokesperson for the BSOM and the Division.

The Vice Chancellor and Dean serves as a direct liaison between the BSOM, the Division of Health Sciences, and the Vidant Health System, serving as the chief contact with the CEO of Vidant Health and the President of Vidant Medical Center for all matters relating to the BSOM and/or the Division, clinical care, education, research, and the practice of medicine. He/she is an ex officio member of the Board of Trustees of the Vidant Medical Center (VMC). This includes strategic clinical and operational interactions between the institutions.

The Vice Chancellor and Dean is responsible for overseeing and coordinating all planning activities for the BSOM and the Division and implements University policies and develops BSOM/Division policies and procedures as necessary to comply with University policy. Strategic planning and implementation (both short term and long term), as well as School/Division budget management and administration are also under his/her purview. This includes collaborating with other relevant university leaders in the budgeting and allocation of fiscal, physical, and human resources in the BSOM and Division.

The Vice Chancellor and Dean serves as the Chief Executive Officer (CEO) of ECU Physicians, the clinical enterprise of the BSOM, with responsibilities for financial, strategic and operational activities. The financial stability of the BSOM is dependent on multiple factors, including the clinical revenues, state appropriations, extramural funding, philanthropic successes, and other sources. The Vice Chancellor and Dean carries the responsibility of bringing together these diverse sources so that the BSOM can continue to build programs, recruit and retain top talent, and provide leadership in teaching, research, clinical care, and public service. He/She makes periodic reports to the Chancellor and ECU Board of Trustees regarding the financial and operational status of ECU Physicians.

The Vice Chancellor and Dean is responsible for the recruitment, selection and evaluation of health care executives in the BSOM and the Division of Health Sciences, in consultation with applicable principals when appropriate. The Vice Chancellor and Dean will supervise and mentor department chairs, center directors, and other leaders within the BSOM and the Division, to assure that future leaders and opportunities for succession are developed. As the senior administrative officer for the Division of Health Sciences, the Vice Chancellor and Dean has delegated authority to execute on behalf of the University all faculty appointments, non-faculty professional appointments, and all other personnel actions in the Division of Health Sciences, except the award of permanent tenure and faculty promotion in academic rank. After advice and consultation with appropriate faculty committees when necessary, the Vice Chancellor and Dean reviews and recommends appropriate faculty personnel matters.

The Vice Chancellor and Dean maintains a work environment that fosters and rewards outstanding performance; requiring the highest standards of quality in the delivery of clinical services; and research compliance in the BSOM and the Division. The Vice Chancellor and Dean serves as senior executive for BSOM and the Division for all externally funded research, internally funded investigations, clinical trials, and other forms of scholarship; and works in concert with appropriate University officials that carry institutional authority to perform the duties of that position. The University & Medical Center

Institutional Review Board (UMC-IRB) has the responsibility to protect the rights and welfare of human subjects engaged in research at the University. Continuing the growth of the research enterprise, the successful implementation of projects, and ensuring industry standards for Clinical Trials are expectations of the Vice Chancellor and Dean.

The Vice Chancellor and Dean is responsible for all educational programs of the BSOM, including those offered in affiliated settings for clinical education. The Vice Chancellor and Dean and his/her staff are responsible for curriculum, selection and promotion of students, and for maintaining the accreditation of the BSOM and its programs. The Vice Chancellor and Dean is responsible for maintaining the BSOM's accreditation by the Liaison Committee for Medical Education and SACS, while introducing innovative educational methodologies into the relevant curricula.

The Vice Chancellor and Dean will assume additional duties as assigned and as requested by the ECU Chancellor and/or the ECU Board of Trustees.

Other responsibilities include:

Lead the growth of the BSOM's academic infrastructure, especially in research, to increase the School's national recognition in conjunction with the Vice Chancellor for Research, Economic Development, and Engagement.

Responsible for all accreditations and regulatory compliance related to the research and clinical missions.


Responsible for Division's Centers and Institutes. Encourage and support interdisciplinary research and education opportunities between BSOM and other units throughout the university.

Approve space resource assignments in all Division facilities and planning for renovation, construction and acquisition of facilities, as coordinated with appropriate University officials.

Carry final responsibility and initial signature authority for all agreement contracts dealing with professional medical contractual services with agencies and institutions external to the University, per University policy.

Serve as the primary fund-raiser for the School, in concert with the ECU Medical & Health Sciences Foundation.

East Carolina University
 Health Sciences Division
 Vice Chancellor for Health Sciences
 6065-6000-HS01
 August 2, 2018



EAST CAROLINA UNIVERSITY
CURRICULUM VITAE

Date Prepared: 08/01/2018

Name: Mark A. Stacy, M.D.

Primary academic appointment: Department of Medicine

Primary academic department: Neurology

Present academic rank and title:

Professor with Tenure, Department of Medicine
Dean, Brody School of Medicine at East Carolina University
Senior Associate Vice Chancellor for Medical Affairs
Interim Vice Chancellor for Health Sciences

Date and rank of first ECU Faculty appointment: Professor with Tenure; 08/31/2017

Medical Licensure: North Carolina License #: 200300890

Date of License: 5/4/2017

Specialty certification(s) and dates:

American Academy of Neurology and Psychiatry 1992

Date of birth: May 4, 1959 **Place:** Cape Girardeau, Missouri, USA

Citizen of: United States

Education:	Institution	Date	Degree
High School	Cape Girardeau Central High School	1977	
College	Southeast Missouri State University, Cape Girardeau, Missouri	1977 –1981	B.S.
Graduate School	University of Missouri	1981 –1982	
Professional School	University of Missouri Columbia, Missouri	1982 –1986	M.D.

Professional training and academic career:

<u>Institution</u>	<u>Position/Title</u>	<u>Dates</u>
Brody School of Medicine at East Carolina University Division of Health Sciences East Carolina University	Dean Senior Associate Vice Chancellor	2017 – present 2017 – present
Duke University Medical Center	Vice Dean for Clinical Research	2011 – 2017
Duke University Medical Center	Professor of Neurology with Tenure	2010 – 2017
Duke University Medical Center	Associate Dean for Clinical Research	2009 – 2011
Duke Institute of Brain Science	Faculty member	2009 – 2017
Duke University Medical Center	Associate Professor of Medicine/Neurology with Tenure	2006 – 2010
Duke University Medical Center	Associate Professor of Medicine/Neurology without Tenure	2003 – 2006
Duke University Medical Center	Director, Neurology Clinical Research Organization	2005 - 2010
Duke University Medical Center	Chief Operations Officer, Neurology Clinical Research Organization	2004 - 2005
Duke University Medical Center	Director, Movement Disorders Center	2003 – 2017
Durham VA Hospital	Attending Physician	2003 – 2004
Muhammad Ali Parkinson Research Center, Barrow Neurological Institute, St. Joseph's Hospital	Director	1997 – 2003
Attending Neurologist		1996 – 2003

Professional training and academic career: (continued)

University of Missouri, Director, Parkinson's Disease Clinic and Movement Disorders Center		1992 – 1996
University of Missouri School of Medicine	Assistant Professor of Neurology	1991 – 1996
Harry Truman Memorial Veterans Hospital	Neurology Consultant	1991 – 1996
Baylor College of Medicine, Houston	Fellowship in Movement Disorders	1990 – 1991
Hahnemann University, Philadelphia	Clinical Instructor of Neurology	1989 – 1990
Hahnemann University, Philadelphia	Chief Resident in Neurology	1989 – 1990
Hahnemann University, Philadelphia	Neurology Resident	1987 – 1990
St. Mary's Hospital, St. Louis	Internal Medicine Internship	1986 – 1987

Publications (Refereed Journals):

1. **Stacy M**, Jankovic J. Tardive dyskinesia. *Curr Opin Neurol Neurosurg* 1991;3:343-9.
2. **Stacy M**, Jankovic J. Tardive tremor. *Mov Disord* 1992;7:53-7.
3. **Stacy M**, Jankovic J. Differential diagnosis of Parkinson's disease and the Parkinsonism plus syndromes. *Neurol Clin* 1992;10:341-60.
4. **Stacy M**, Jankovic J. Current approaches in the treatment of Parkinson's disease. *Ann Rev Med* 1993;44:431-40.
5. **Stacy M**, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. *Neurology* 1993;43:937-41.
6. Sahota PK, **Stacy M**. Pain as a Manifestation of Seizure Disorder. *Clinical Electro-Encephalography* 1993;24:63-6.
7. Nair J, **Stacy M**. A case of salicylate induced aseptic meningitis. *Psychosomatics* 1993;37:2.
8. **Stacy M**, Jankovic J. Childhood dystonia. *Ped Ann*: 1993;22:53-8.
9. Logan-Clubb L, **Stacy M**. An open-labeled assessment of side effects associated with interferon 1-Beta in the treatment of multiple sclerosis. *J Neurosci Nurs* 1995;27:344-7.
10. **Stacy M**, Brownlee HJ. Treatment options for early Parkinson's disease. *Amer Fam Phys* 1996;53:1281-7.
11. Menditto AA, Beck NC, Stuve P, Fischer JA, **Stacy M**, Logue MB, Baldwin LJ. Effectiveness of clozapine and a social learning program for severely disabled psychiatric inpatients. *Psychiatric Services* 1996;47:46-52.
12. Childers M, **Stacy M**, Cooke D, Stonnington HH. Comparison of two injection techniques using botulinum toxin in spastic hemiplegia. *Am J Phys Med Rehabil* 1996;75:462-9.
13. **Stacy M**. Treatment of non-motor symptoms in Parkinson's disease. *CNS Spectrums* 1998;3:41-5.
14. Shill H, **Stacy M**. Respiratory function in Parkinson's disease. *Clinical Neuroscience* 1998; 5:131-5.
15. **Stacy M**. Managing late complications of Parkinson's disease. *Medical Clinics of North America* 1999;83:469-81.
16. Shill H, **Stacy M**. Malignant catatonia secondary to sporadic encephalitis lethargica. *J Neurol Neurosurg Psychiatry* 2000;69:402-3.
17. **Stacy M**. Pharmacotherapy for advanced Parkinson's disease. *Pharmacotherapy* 2000;20:S8-16.
18. **Stacy M**. Idiopathic cervical dystonia: An overview. *Neurology* 2000;55(Suppl 5):S52-8.
19. Mahant P, **Stacy M**. Normal aging and movement disorders. *Neurol Clin N Amer* 2000;19:553-63.

Publications (Refereed Journals): (continued)

20. Shoulson I, Penney J, McDermott M, Schwid S, Kayson E, Chase T, Fahn S, Greenamyre JT, Lang A, Siderowf A, Pearson N, Harrison M, Rost E, Colcher A, Lloyd M, Matthews M, Pahwa R, McGuire D, Lew MF, Schuman S, Marek K, Broshjeit S, Factor S, Brown D, Feigin A, Mazurkiewicz J, Ford B, Jennings D, Dilllon S, Comella C, Blasucci L, Janko K, Shulman L, Wiener W, Bateman-Rodriguez D, Carrion A, Suchowersky O, Lafontaine AL, Pantella C, Siemers E, Belden J, Davies R, Lannon M, Grimes D, Gray P, Martin W, Kennedy L, Adler C, Newman S, Hammerstad J, Stone C, Lewitt P, Bardram K, Mistura K, Miyasaki J, Johnston L, Cha JH, Tennis M, Panniset M, Hall J, Tetrud J, Friedlander J, Hauser R, Gauger L, Rodnitzky R, Deleo A, Dobson J, Seeberger L, Dingmann C, Tarsy D, Ryan P, Elmer L, Ruzicka D, **Stacy M**, Brewer M, Locke B, Baker D, Casaceli C, Day D, Florack M, Hodgeman K, Laroia N, Nobel R, Orme C, Rexo L, Rothenburgh K, Sulimowicz K, Watts A, Wratni E, Tariot P, Cox C, Leventhal C, Alderfer V, Craun AM, Frey J, McCree L, McDermott J, Cooper J, Holdich T, Read B; Parkinson Study Group. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. *Neurology* 2001;56:455-62.
21. DeStefano AL, Golbe LI, Mark MH, Lazzarini AM, Maher NE, Saint-Hilaire M, Feldman RG, Guttman M, Watts RL, Suchowersky O, Lafontaine AL, Labelle N, Lew MF, Waters CH, Growdon JH, Singer C, Currie LJ, Wooten GF, Vieregge P, Pramstaller PP, Klein C, Hubble JP, **Stacy M**, Montgomery E, MacDonald ME, Gusella JF, Myers RH. Genome-wide scan for Parkinson's disease: the GenePD Study. *Neurology* 2001;57:1124-6.
22. Baev K, Greene A, Marciano F, Samanta J, Shetter A, Smith K, **Stacy M**, Spetzler R. Physiology and pathophysiology of cortico-basal ganglia-thalamocortical loops: Theoretical and practical aspects. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 2002;26:771-804.
23. **Stacy, M**. Sleep disorders in Parkinson's disease: Epidemiology and management. *Drugs & Aging* 2002;19:733-9.
24. Maher NE, Golbe LI, Lazzarini AM, Mark MH, Currie LJ, Wooten GF, Saint-Hilaire M, Wilk JB, Volcjak J, Maher JE, Feldman RG, Guttman M, Lew M, Waters CH, Schuman S, Suchowersky O, Lafontaine AL, Labelle N, Vieregge P, Pramstaller PP, Klein C, Hubble J, Reider C, Growdon J, Watts R, Montgomery E, Baker K, Singer C, **Stacy M**, Myers RH. Epidemiologic study of 203 sibling pairs with Parkinson's disease: The GenePD Study. *Neurology* 2002;58:79-84.
25. DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M, Montgomery E, Waters CH, Singer C, Watts RL, Currie LJ, Wooten GF, Maher NE, Wilk JB, Sullivan KM, Slater KM, Saint-Hilaire MH, Feldman RG, Suchowersky O, Lafontaine AL, Labelle N, Growdon JH, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Reider CR, **Stacy M**, MacDonald ME, Gusella JF, Myers RH. PARK3 influences age at onset in Parkinson disease: A genome scan in the GenePD Study. *Am J Hum Genet* 2002;70:1089-95.
26. Joyce JN, Ryoo HL, Beach, TB, Caviness JN, **Stacy M**, Gurevich EV, Reiser M, Adler CH. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors. *Brain Res* 2002;955:138-52.
27. Shill HA, **Stacy M**. Respiratory complications of Parkinson's disease. *Semin Respir Crit Care Med* 2002;23:261-6.
28. Driver-Dunckley E, Samanta J, **Stacy M**. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. *Neurology* 2003;61:422-3.
29. Longstaff MG, Mahant PR, **Stacy MA**, Van Gemmert AW, Leis BC, Stelmach GE. Discrete and dynamic scaling of the size of continuous graphic movements of Parkinsonian patients and elderly controls. *J Neurol Neurosurg Psychiatry* 2003;74:299-304.
30. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr., Lozano AM, Penn RD, Simpson RK, **Stacy M**, Wooten GF; ICV GDNF Study Group. Implanted intracerebroventricular Glial cell line-derived neurotrophic factor. Randomized, double-blind trial of glial cell line-derived neurotrophic factor. *Neurology* 2003;60:69-73.

Publications (Refereed Journals): (continued)

31. Karamohamed S, DeStefano AL, Wilk JB, Shoemaker CM, Golbe LI, Mark MH, Lazzarini AM, Suchowersky O, Labelle N, Guttman M, Currie LJ, Wooten GF, **Stacy M**, Saint-Hilaire M, Feldman RG, Sullivan KM, Xu G, Watts R, Growdon J, Lew M, Waters C, Vieregge P, Pramstaller PP, Klein C, Racette BA, Perlmutter JS, Parsian A, Singer C, Montgomery E, Baker K, Gusella JF, Fink SJ, Myers RH, Herbert A; GenePD study. A haplotype at the PARK3 locus influences onset age for Parkinson's disease: the GenePD study. *Neurology* 2003;61:1557-61.
32. **Stacy M**. Apomorphine North American clinical experience. *Neurology* 2004;62 (suppl): S18-21.
33. Koller WC, **Stacy M**. Other formulations for apomorphine and future considerations for subcutaneous injection therapy. *Neurology* 2004;62(suppl):S22-6.
34. Scott WK, Zhang F, Stajich JM, Scott BL, **Stacy M**, Vance JM. Family-based case-control study of cigarette smoking and Parkinson disease. *Neurology* 2005;64:442-7. **Publications (Refereed Journals):** (continued)
35. **Stacy M**, Bowron A, Guttman M, Hauser R, Hughes K, Larsen JP, Lewitt P, Oertel W, Quinn N, Sethi K, Stocchi F. Identification of motor and non-motor wearing-off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment. *Mov Disord* 2005;20:726-33.
36. Karamohamed S, Golbe LI, Mark MH, Lazzarini AM, Suchowersky O, Labelle N, Guttman M, Currie LJ, Wooten GF, **Stacy M**, Saint-Hilaire M, Feldman RG, Liu J, Shoemaker CM, Wilk JB, De Stefano AL, Latourelle JC, Xu G, Watts R, Growdon J, Lew M, Waters C, Vieregge P, Pramstaller PP, Klein C, Racette BA, Perlmutter JS, Parsian A, Singer C, Montgomery E, Baker K, Gusella JF, Herbert A, Myers RH. Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study. *Mov Disord* 2005;20:1188-91.
37. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, **Stacy M**, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A; Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. *Arch Neurol* 2004;61:1044-53.
38. Kolls BJ, **Stacy M**. Apomorphine: An Overview of Clinical Use. *Aging Health* 2005;1:193-202.
39. Lang, AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Hutchinson M, Kelly P, Dalvi A, Scott B, **Stacy M**, Turner D, Wooten VGF, Elias WJ, Laws ER, Dhawan V, Stoessl AJ, Matcham J, Coffey RJ, Traub M. A multicenter, randomized, double-blind, placebo controlled trial of liatermin (r-metHuGDNF) administered by bilateral Intraputaminial infusion to patients with idiopathic Parkinson's disease. *Ann Neurol* 2006;59:459-66.
40. Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, **Stacy M**, Koller WC, Schwarzman L, Wu S-C, Ph.D., Hulihan JF on behalf of the Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: A double-blind, placebo-controlled trial. *Neurology* 2006;66:672-7.
41. Hancock DB, Martin ER, Fujiwara K, **Stacy MA**, Scott BL, Stajich JM, Jewett R, Li Y-L, Hauser MA, Vance JM, Scott WK. NOS2A and the modulating effect of cigarette smoking in Parkinson disease. *Ann Neurol* 2006;60:366-73.
42. Kolls B, **Stacy M**. Apomorphine: A rapid rescue agent for motor and non-motor fluctuations in advanced Parkinson's disease. *Clinical Neuropharmacol* 2006;29:292-301.
43. **Stacy M**, Hauser R, Oertel W, Schapira A, Sethi K, Stocchi F, Tolosa E. End of Dose Wearing-Off in Parkinson's Disease: a 9-question survey assessment. *Clin Neuropharmacol* 2006;29:312-21.

Publications (Refereed Journals): (continued)

44. Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler C, Brashear A, Comella CL, Gordon M, Riley D, Sethi K, Singer C, **Stacy M**, Tarsy D, Zouhair Atassi M. Clinico-immunologic aspects of Botulinum Toxin Type B Treatment of Cervical Dystonia. *Neurology* 2006;67:2233-5.
45. **Stacy M**, Hauser R, and the Wearing Off Study Group. Development of a Wearing-Off Patient Questionnaire to facilitate recognition of the motor and non-motor symptoms of wearing-off in Parkinson's disease. *J Neural Transm* 2007;114:211-7.
46. Hancock DB, Martin ER, Stajich JM, **Stacy MA**, Scott BL, Vance JM, Scott WK. Smoking, caffeine and nonsteroidal anti-inflammatory drugs in families with Parkinson's disease. *Arch Neurol* 2007;64:576-80
47. Pahwa R, **Stacy MA**, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL on behalf of the EASE-PD Adjunct Study Investigators. A randomized, double-blind, placebo-controlled, parallel-group study of ropinirole 24-hour prolonged release as adjunctive therapy in patients with Parkinson's disease not optimally controlled on L-dopa (EASE-PD Adjunct study). *Neurology* 2007;68:1108-15.
48. Jankovic J, **Stacy M**. Medical management of motor complications in Parkinson's disease patients on carbidopa/levodopa. *CNS Drugs* 2007;21:667-92.
49. **Stacy M**, Elble RJ, Ondo, Wu S-C, Hulihan J for the Tremor Rating Scale Study Group. Assessment of Inter-Rater and Intra-Rater Reliability of the Tremor Rating Scale (TRS) in Essential Tremor. *Mov Disord* 2007;22:833-8.
50. Chou KL, **Stacy MA**. Skin rash associated with Sinemet does not equal levodopa allergy. *Neurology* 2007;68:1078-9.
51. Ravina B, Marder K, Fernandez H, Friedman J, McDonald W, Murphy D, Aarsland D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, **Stacy M**, Gwinn-Hardy K, Voon V, Goetz C. Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS/NIMH Work Group. *Mov Disord* 2007;22:1061-8.
52. Galpern WR, **Stacy M**. Management of impulse control disorders in Parkinson's disease. *Curr Treat Options Neurol* 2007;9:189-97.
53. Menon R, **Stacy M**. Apomorphine in the treatment of Parkinson's disease. *Exp Opin Pharmacother* 2007;8:1941-50.
54. **Stacy M**, Silver D. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. *Parkinsonism & Related Disorders* 2008;14:85-92.
55. **Stacy M**, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X on behalf of the COMPASS-1 study group. The sensitivity and specificity of a 9-item Wearing-Off Questionnaire. *Parkinsonism Relat Disord* 2008;14:205-12.
56. Kulkarni AS, Balkrishnan R, Kirsch J, Anderson RT, Edin HM, **Stacy M**. Medication adherence and associated outcomes in Medicare HMO-enrolled older adults with Parkinson's Disease: A longitudinal cohort study. *Mov Disord* 2008;23:359-65.
57. **Stacy M**, Galbreath A. Optimizing long-term therapy for Parkinson's disease: levodopa, dopamine agonists, and treatment-associated dyskinesia (part 1). *Clin Neuropharmacol* 2008;31:51-6.
58. Hancock DB, Martin ER, Mayhew GM, Jeffrey M Stajich JM, Jewett R, **Stacy MA**, Scott BL, Vance JM, Scott WK. Pesticide exposure and risk of Parkinson's disease: a family-based case-control study. *BMC Neurology* 2008;8:6-10.
59. Ferrara J, Gupta D, Foster E, Garman K, **Stacy M**. Extraocular muscle dystonia due to acquired (non-Wilsonian) hepatocerebral degeneration. *Mov Disord* 2008;23:875-8.
60. **Stacy M**, Galbreath A. Optimizing long-term therapy for Parkinson's disease: treatment-associated dyskinesia (part 2). *Clin Neuropharmacol* 2008;31:120-5.
61. **Stacy M**, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, Sussman NM. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson's disease. *Neurology* 2008;70:2233-40.
62. **Stacy, M**. Epidemiology, clinical presentation, and diagnosis of cervical dystonia. *Neurol Clin N Amer* 2008;26(suppl 1):S23-42.

Publications (Refereed Journals): (continued)

63. Ferrara JM, **Stacy M**. Impulse control disorders and Parkinson's disease. *CNS Spectr* 2008;13:690-8.
64. Hallett M, Evinger C, Jankovic J, **Stacy M**; BEBRF Workshop. Update on Blepharospasm. *Neurology* 2008;71:1275-82.
65. Sommer D, **Stacy M**. Epidemiology and Pathophysiology of Restless Legs Syndrome. *Expert Rev Neurother* 2008;8:1829-39.
66. Sommer DB, **Stacy, M**. What's in the pipeline for the treatment of Parkinson's Disease? *Exp Rev Neurotherapeutics* 2008;8:1829-39.
67. Wingo TS, Evatt M, Scott B, Freeman A, **Stacy M**. Impulse control disorders arising in three patients treated with rotigotine. *Clin Neuropharmacol* 2009;32:59-62.
68. Kuncel AM, Turner DA, Ozelius LJ, Greene PE, Grill WM, **Stacy M**. Thalamic deep brain stimulation for myoclonus in a patient with inherited myoclonus-dystonia and tremor. *Clin Neurol Neurosurg Clin Neurol Neurosurg*. 2009;111:303-6.
69. Shill HA, De La Vega FJ, Samanta J, **Stacy M**. Motor learning in essential tremor. *Mov Disord* 2009 Feb 25. *Mov Disord*. 2009;24:926-8.
70. Shill HA, **Stacy M**. Update on ropinirole in the treatment of Parkinson's disease. *Neuropsychiatr Dis Treat* 2009;5:33-6.
71. **Stacy, M**. Medical Management of Parkinson's Disease. *Neurol Clin* 2009;27:605-31.
72. Evans AH, Strafella AP, Weintraub D, **Stacy M**. Impulsive and compulsive behaviors in Parkinson's disease. *Mov Disord*. 2009;24:1561-70.
73. Park A, **Stacy M**. Non-motor symptoms in Parkinson's Disease. *J Neurol*. 2009;256(Suppl 3):293-8.
74. **Stacy M**, Murck H, Kroenke K. Responsiveness of motor and non-motor symptoms of Parkinson's disease to dopaminergic therapy. *Prog Neuropsychopharmacol Biol Psychiatry*. 2010;34:57-61.
75. Weintraub D, Koester J, Potenza MN, Siderowf AD, **Stacy M**, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Impulse control disorders in Parkinson's disease: A cross-sectional study of dopaminergic therapy and other clinical features in 3,090 Patients. *Arch Neurol* 2010;67:589-95.
76. Hersh BP, Earl NL, Hauser RA, **Stacy M**. Early treatment benefits or ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. *Mov Disord* 2010;25:927-31.
77. **Stacy M**. The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease. *J Neural Transm* 2010;117:837-46.
78. Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, **Stacy M**, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, Kordower JH, Olanow CW. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. *Lancet Neurol*. 2010;9:1164-72.
79. Weintraub D, Sohr M, Potenza MN, Siderowf AD, **Stacy M**, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. *Ann Neurol* 2010;68:963-8.
80. Peckham EL, Lopez G, Shamim EA, Richardson SP, Sanku S, Malkani R, **Stacy M**, Mahant P, Crawley A, Singleton A, Hallett M. Clinical features of patients with blepharospasm: a report of 240 patients. *Eur J Neurol*. 2011 Mar;18(3):382-6.
81. Antonini A, Martinez-Martin P, Chaudhuri RK, Merello M, Hauser R, Katzenschlager R, Odin P, **Stacy M**, Stocchi F, Poewe W, Rascol O, Sampaio C, Schrag A, Stebbins GT, Goetz CG. Wearing-off scales in Parkinson's disease: critique and recommendations. *Mov Disord*. 2011 Oct;26(12):2169-75.
82. Hickey P, **Stacy M**. Available and emerging treatments for Parkinson's disease: a review. *Drug Des Devel Ther*. 2011;5:241-54.
83. Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, Weintraub D, Wunderlich GR, **Stacy M**. Impulse control disorders in Parkinson disease: a multicenter case--control study. *Ann Neurol*. 2011;69:986-96.
84. **Stacy M**. Nonmotor symptoms in Parkinson's disease. *Int J Neurosci* 2011;121(Suppl 2):9-17.

Publications (Refereed Journals): (continued)

85. Jankovic J, Adler CH, Charles PD, Comella C, **Stacy M**, Schwartz M, Sutch SM, Brin MF, Papapetropoulos S. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE). *BMC Neurol* 2011;11:140.
86. Hickey P, **Stacy M**. The surgical management of Parkinson's Disease. *Neurodegenerative Disease Management*. 2011;1:203-215.
87. Pourcher E, Fernandez HH, **Stacy M**, Mori A, Ballerini R, Chaikin P. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. *Parkinsonism Relat Disord* 2012;18:178-84.
88. Brashear A, Cook JF, Hill DF, Amponsah A, Snively B, Light L, Boggs N, Suerken CK, **Stacy M**, Ozelius L, Sweadner KJ, McCall WV. Psychiatric Disorders in Rapid-Onset Dystonia Parkinsonism. *Neurology* 2012;79:1168-73.
89. Hickey P, **Stacy M**. Adenosine A2A Antagonists in Parkinson's Disease: What's Next? *Curr Neurol Neurosci Rep*. 2012;12:376-85.
90. Barbano RL, Hill DF, Snively BM, Light LS, Boggs N, McCall WV, **Stacy M**, Ozelius L, Sweadner KJ, Brashear A. New triggers and non-motor findings in a family with rapid-onset dystonia-parkinsonism. *Parkinsonism Relat Disord*. 2012;18:737-41.
91. Park A, **Stacy M**. Istradefylline for the treatment of Parkinson's disease. *Expert Opin Pharmacother*. 2012;13:111-4.
92. Park A, **Stacy M**. Dopamine-Induced Non-Motor Symptoms of Parkinson's Disease. *Parkinson's Disease* 2011;2011:485063. Epub 2011 Apr 11.
93. Brashear A, Mink JW, Hill DF, Boggs N, McCall WV, **Stacy M**, Snively B, Light LS, Sweadner KJ, Ozelius LJ, Morrison L. ATP1A3 mutations in infants: a new rapid-onset dystonia-Parkinsonism phenotype characterized by motor delay and ataxia *Dev Med Child Neurol*. 2012 Nov;54(11):1065-7.
94. Boland D, **Stacy M**. The Economic and Quality of Life Burden Associated with Parkinson's Disease: A Focus on Symptoms. *Amer J Managed Care*. 2012;12(suppl):s168-75.
95. Brashear A, Cook JF, Hill DF, Amponsah A, Snively B, Boggs N, Suerken CK, Haq I, **Stacy M**, Ozelius L, Sweadner KJ, McCall WV. Cognitive Impairment in Rapid-Onset Dystonia Parkinsonism. *Mov Disord Neurology*. 2012 Sep 11;79:1168-73.
96. Hattori N, Fujimoto K, Kondo T, Murata M, **Stacy M**. Patient perspectives on Parkinson's disease therapy in Japan and the United States: results of two patient surveys. *Patient Relat Outcome Meas*. 2012;3:31-8.
97. Snyder DC, Epps S, Beresford HF, Ennis C, Levens JS, Woody SK, Tcheng JE, **Stacy M**, Nahm M. Research Management Team (RMT): A Model for Research Support Services at Duke University. *Clinical and Translational Science* 2012;5:464-469.
98. Hickey P, **Stacy M**. AAV2-neurturin (CERE-120) for Parkinson's Disease. *Expert Opin Biol Ther*. 2013;13:137-45.
99. Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, **Stacy M**, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Ge S. Which dyskinesia scale best detects treatment response? A double-blind placebo controlled trial using multiple dyskinesia measures. *Mov Disord*. 2013;28:341-6.
100. Bartus RT, Baumann TL, Siffert J, Herzog CD, Alterman R, Boulis N, Turner D, **Stacy M**, Lang AE, Lozano AM, Olanow CW. Safety/Feasibility of Targeting the Substantia Nigra with AAV2-Neurturin in Parkinson's Disease. *Neurology* 2013;80:1698-701.
101. Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, **Stacy M**, Ondo W, O'Connell M, Gupta S; IPX066 ADVANCE-PD investigators. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. *Lancet Neurol* 2013;12:346-56.

Publications (Refereed Journals): (continued)

102. Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, **Stacy M**, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C. AFQ056 in Parkinson patients with L-dopa-induced dyskinesia: 13-week randomized, controlled, dose-finding study. *Mov Disord* 2013;28:1838-46.
103. Cook JF, Hill DF, Snively BM, Boggs N, Suerken CK, Haq I, **Stacy M**, McCall WV, Ozelius LJ, Sweadner KJ, Brashear A. Cognitive impairment in rapid-onset dystonia-parkinsonism. *Mov Disord*. 2014;29:344-50.
104. Charles PD, Adler CH, **Stacy M**, Comella C, Jankovic J, Manack Adams A, Schwartz, M, Brin MF. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). *J Neurol* 2014;261:1309-19.
105. Oblak AL, Hagen MC, Sweadner KJ, Haq I, Whitlow CT, Maldjian JA, Epperson F, Cook JF, **Stacy M**, Murrell JR, Ozelius LJ, Brashear A, Ghetti B. Rapid-onset dystonia-parkinsonisms associated with the 1758s mutation of the ATP1A3 gene: a neuropathologic and neuroanatomical study of four siblings. *Acta Neuropathol* 2014;128:81-98.
106. Jakel RJ, **Stacy M**. Parkinson's Disease Psychosis. *J Parkinsonism and RLS* 2014;4:41-51.
107. Weintraub D, David AS, Evans AH, Grant JE, **Stacy M**. Clinical spectrum of impulse control disorders in Parkinson's Disease. *Mov Disord* 2015;30:121-7.
108. O'Reilly EK, Hassell NJ, Snyder DC, Natoli S, Liu I, Rimmler J, Amspacher V, Burnett BK, Parrish AB, Berglund JP, **Stacy M**. ClinicalTrials.gov reporting: strategies for success at an academic health center. *Clin Transl Sci*. 2015;8:48-51.
109. Jankovic J, Comella C, Adler CH, Charles D, **Stacy M**, Schwartz M, Manack A, Brin MF. Primary Results from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE). *J Neurol Sci*. 2015;349:84-93.
110. Olanow WC, Bartus RT, Baumann TL, Factor S, Boulis N, **Stacy M**, Turner DA, Marks W, Larson P, Starr PA, Jankovic J, Simpson R, Watts R, Guthrie B, Poston K, Henderson JM, Stern M, Baltuch G, Goetz CG, Herzog C, Kordower JH, Alterman R, Lozano AM, Lang AE. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. *Ann Neurol*. 2015;78(2):248-57. doi: 10.1002/ana.24436.
111. Selker HP, Buse JB, Califf RM, Carter R, Cooper DM, Davis J, Ford DE, Galassetti P, Guay-Woodford L, Huggins GS, Kasper A, Kiebertz K, Kirby A, Klein AK, Kline J, O' Neill RT, Rape M, Reichgott DJ, Rojevsky S, Rosenthal GE, Rubinstein EP, Shepherd A, **Stacy M**, Terrin N, Wallace M, Welch L. CTSA Consortium Consensus Scientific Review Committee (SRC) Working Group Report on the SRC Processes. *Clin Transl Sci* 2015;8:623-31. doi: 10.1111/cts.12306.
112. Park A, **Stacy M**. Disease-Modifying Drugs in Parkinson's Disease, *Drugs* 2015 Nov 18. Doi: 10.1007/s40265-015-0497-4 [Epub ahead of print]
113. Cooney JW, **Stacy M**. Neuropsychiatric Issues in Parkinson's Disease. *Curr Neurol Neurosci Rep*. 2016 May;16(5):49.
114. Snyder DC, Brouwer RN, Ennis CL, Spangler LL, Ainsworth TL, Budinger S, Mullen C, Hawley J, Uhlenbrauck G, **Stacy M**. Retooling institutional support infrastructure for clinical research. *Contemp Clin Trials*. 2016 Apr 26;48:139-145.
115. Hickey P, **Stacy M**. Deep Brain Stimulation: A Paradigm Shifting Approach to Treat Parkinson's Disease. *Front Neurosci*. 2016 Apr 28;10:173. doi:10.3389/fnins.2016.00173.
116. Bauman TL, Siffert J, Lang AE, Boulis N, Alterman R, Turner D, **Stacy M**, Herzog CD, Ostrove JM, Lozano AM, Olanow CW, Bartus RT. Rationale, Design and Implementation of a Randomized, Multi-center, Sham-surgery Controlled, Trial Testing the Efficacy of Combined Substantia Nigral and Putaminal Delivery of AAV2-Neurturin (CERE-120) Gene Therapy in Parkinson's Disease. *Neurology* (in press)

Publications (Refereed Journals): (continued)

117. Molho ES, **Stacy M**, Gillard P, Charles D, Adler CH, Jankovic J, Schwarz M, Brin MF. Impact of Cervical Dystonia on Work Productivity: An Analysis from a Patient Registry. *Mov Disord Clin Pract* 2016 Mar-Apr;3(2):130-138. PubMed PMID: 27774495; PubMed Central PMCID: PMC5064605.
118. Rittiner JE, Caffall ZF, Hernández-Martínez R, Sanderson SM, Pearson JL, Tsukayama KK, Liu AY, Xiao C, Tracy S, Shipman MK, Hickey P, Johnson J, Scott B, **Stacy M**, Saunders-Pullman R, Bressman S, Simonyan K, Sharma N, Ozelius LJ, Cirulli ET, Calakos N. Functional Genomic Analyses of Mendelian and Sporadic Disease Identify Impaired eIF2 α Signaling as a Generalizable Mechanism for Dystonia. *Neuron*. 2016 Dec 21;92(6):1238-1251. doi: 10.1016/j.neuron.2016.11.012. PubMed PMID: 27939583.
119. Hickey PT, Kuchibhatla M, Scott B, Gauger L, **Stacy MA**. Dopamine Transporter Imaging has no Impact on Functional Outcomes in de Novo Probable Parkinson's Disease. *J Parkinsons Dis*. 2017;7(2):279-287. doi: 10.3233/JPD-160937. PubMed PMID: 28339403.
120. Goetz CG, Stebbins GT, Chung KA, Nicholas AP, Hauser RA, Merkitich D, **Stacy MA**. Topiramate as an adjunct to amantadine in the treatment of dyskinesia in Parkinson's Disease: A randomized, double-blind, placebo-controlled multicenter study. *Mov Disord*. 2017 Jun 24. doi: 10.1002/mds.27092. [Epub ahead of print] PubMed PMID: 28646494.
121. Chou KL, **Stacy M**, Simuni T, Miyasaki J, Oertel WH, Sethi K, Fernandez HH, Stocchi F. The spectrum of "off" in Parkinson's disease: What have we learned over 40 years? *Parkinsonism Relat Disord*. 2018 Feb 2. pii: S1353-8020(18)30037-3. doi: 10.1016/j.parkreldis.2018.02.001. [Epub ahead of print] Review. PubMed PMID: 29456046.

Publications (non-refereed Journals):

1. **Stacy M**. Treatment choices and timing are key to managing Parkinson's disease. *Geriatrics* 1999;54:44-9.
2. Connor G, Ondo W, **Stacy M**. Essential Tremor: A Practical Guide to Evaluation, Diagnosis, and Treatment. *Clinician* 2001;19:1-14,

Chapters in books:

1. Mancall EL, **Stacy M**. Cervical Spondylosis. In: Current Therapy in Neurologic Disease -3. Johnson RT, ed. B.C. Decker, Inc. Philadelphia. 1990. pp. 64-6.
2. **Stacy M**, Roeltgen DP. Neurologic Infections. In: Pathology of the Aging Nervous System. Duckett S, ed. Lea & Febiger, Philadelphia, 1991. pp. 374-92.
3. **Stacy M**, Jankovic J. Clinical and Neurobiological Aspects of Parkinson's Disease. In: Neurobehavioral Aspects of Parkinson's Disease. Huber SJ, Cummings JL, eds. Oxford University Press, New York. 1992; pp. 10-31.
4. **Stacy M**, Jankovic J. Rare Childhood Movement Disorders Associated with Metabolic and Neurodegenerative Diseases. Movement and Allied Disorders in Childhood. Robertson MM, Eapen V, eds. John Wiley & Sons, Ltd, Chichester, England. 1995. pp.177-198.
5. **Stacy M**, Jankovic J. Movement Disorders. In: Adult Neurology. Bloom C, ed. Mosby, St. Louis, 1997 pp. 267-82.
6. Jankovic J, **Stacy M**. Movement Disorders. In: Textbook of Clinical Neurology. Goetz C, Pappert E, eds., 1998 pp.655-79.
7. **Stacy M**. Gilles de la Tourette's Syndrome and Other Tic Disorders. In: Current Pediatric Therapy, Vol 16. Burg, Wald, Ingelfinger, Polin, eds. 1999 pp. 389-90.
8. **Stacy M**. Catatonia. *Neurobase* 1999, 2001, 2002, 2003, 2004, 2005, 2007, 2008.
9. **Stacy M**. Parkinson's Disease/Amyotrophic Lateral Sclerosis Complex of Guam. *Neurobase* 1999, 2001.
10. **Stacy M**. Progressive Supranuclear Palsy. In: Parkinson's Disease and Movement Disorders. Adler CH, Ahlskog JE, eds. Humana Press, Totowa, NJ 2000 pp. 229-34.
11. **Stacy M**, Tsui J. Limb Dystonia. *Neurobase* 2002, 2003, 2006.

Chapters in books: (continued)

12. **Stacy M.** Dopamine Agonists. In: Handbook of Parkinson's Disease, 3rd Edition. Pahwa R, Lyons K, Koller W, eds. Marcel Dekker, Inc. New York. 2003 pp 407-24.
13. Sathornsumetee S, **Stacy M.** Post-traumatic Movement disorders. Neurobase 2005, 2006, 2008, 2012, 2015.
14. Sathornsumetee S, **Stacy M.**, Roos RP. Amebic meningoencephalitis. Neurobase 2005, 2007.
15. Jurkowski A, **Stacy M.** Taxonomy and Clinical Features of Movement Disorders. In: Animal Models in Movement Disorders, LeDoux M, ed. Elsevier, San Diego 2005 pp 1-12.
16. The Dystonia Study Group. Rating Scales for Dystonia: Assessment of Reliability of 3 scales. Dystonia 4. Raven Press, 2005 pp 329-36.
17. **Stacy M.** Generalized Dystonia and Limb Dystonia. Jankovic J, ed. Seminars in Neurology. Demos Medical Publishing, New York 2005, pp. 23-30.
18. Sathornsumetee S, **Stacy M.** Movement Disorders. In: Adult Neurology, 2nd edition. Corey-Bloom J, ed. Mosby, St. Louis, 2005 pp 256-74.
19. Street V, **Stacy M.** Dopamine Agonists. In: Handbook of Parkinson's Disease, 4th Edition. Pahwa R, Lyons eds. Informa. New York. 2007 pp 335-48
20. **Stacy M.** Case Studies in Parkinson's Disease. In Parkinson's Disease: Questions and Answers, Hauser R, ed. 2007 pp 197-212.
21. **Stacy M.** Clinical Use of the Botulinum Toxins. In Handbook of Dystonia, Stacy M, ed. Taylor & Francis, Philadelphia. 2007 pp 357-69.
22. Menon RN, **Stacy M.** Adenosine A_{2A} Receptor Antagonists in the Treatment of Parkinson's Disease. In Parkinson's Disease: Diagnosis and Clinical Management, Factor SA and Weiner WJ, eds. Butterworth 2007
23. Beuchler R, **Stacy M.** Hemiballismus. In: Movement Disorders: 100 instructive cases. Reich S, ed. Informa, Philadelphia 2008.
24. Sathornsumetee S, **Stacy M.** Movement Disorders. In: Adult Neurology, 2nd edition. Corey-Bloom J, ed. Mosby, St. Louis, 2008
25. **Stacy M.** Parkinson's Disease and Movement Disorders. In: Annual Review of Neurology. Hallet M, ed. Oxford Press, 2008.
26. Samanta JES, **Stacy M.** Progressive Supranuclear Palsy. In: Movement Disorders. Cambridge University Press. Truong D, ed. 2009.
27. Suski V, **Stacy M.** Tic Disorders In: Movement Disorders. Cambridge University Press. Truong D, ed. 2009.
28. Sommer DB, **Stacy M.** Epidemiology and pathophysiology of restless legs syndrome. In: Year in Neurological Disease.
29. Park A, **Stacy M.** Striatonigral Degeneration. In: Encyclopedia of Movement Disorders, Oxford press (in press)
30. **Stacy M.** Faculty Member for *Faculty of 1000 Medicine* ISSN Online:1740-309X. 2008, 2009
 - a. Imaging amyloid deposition in Lewy body diseases, 2008
 - b. Pathologic findings in prospectively ascertained essential tremor subjects, 2008
 - c. Hold Your Horses: Impulsivity, Deep Brain Stimulation, and Medication in Parkinsonism, 2008
 - d. Sodium Oxybate for Excessive Daytime Sleepiness in Parkinson Disease, 2008
 - e. Impulse Control Disorders, 2009
 - f. A controlled trial of antidepressants in patients with Parkinson disease and depression, 2009
31. Stacy M, Jankovic J. Overview of Medical Treatment of Non-motor Features in Parkinson's Disease. In: The Non-Motor and Non-Dopaminergic Features of Parkinson's Disease. Olanow CW, Stocchi F, Lang AE, ed. Blackwell Publishing, New York 2010.
32. Suski V, **Stacy M.** Dopamine Agonists. In: Handbook of Parkinson's Disease, 5th Edition. Pahwa R, Lyons eds. Informa. New York. 2010
33. Sommer D, **Stacy M.** Acquired Torticollis. *BMJ Point of Care*, 2009, 2010.
34. Jakel RJ, **Stacy M.** Catatonia. *Neurobase* 2010, 2012. 2014, 2016.

Chapters in books: (continued)

35. Johnson J, **Stacy M**. Unusual Causes of Tremor. In: Uncommon Causes of Movement Disorders. Cambridge University Press, Galvez-Jiminez N, Tuite P, eds. 2011.
36. Jakel RJ, **Stacy M**. Psychosis and Parkinson's Disease. Ebmeier KP, O'Brien J, Taylor J- P (eds): Psychiatry of Parkinson's Disease. Adv Biol Psychiatry. Basel, Karger, 2012, vol 27, pp 53–60
37. Sommer D, **Stacy M**. Dystonia. In: Handbook of Movement Disorders. Chitnis S, Dewey R ed. Atlas Press, Dallas 2011.
38. **Stacy M**, Hickey P. Stereotypic Movements in a Nurse Referred for the Evaluation of Parkinson's Disease. In: Fernandez, H and Merello, M; Movement Disorders: Unforgettable Cases and Lessons from the Bedside. 1st ed. New York, NY: Demos Medical. 2012.
39. Hickey P, **Stacy M**. Clinical Use of the Botulinum Toxins. In Handbook of Dystonia, 2nd edition. Stacy M, ed. Informa, Philadelphia. 2012.
40. Hickey PT, **Stacy M**. Taxonomy and Clinical Features of Movement Disorders. In: LeDoux, M; Movement Disorders: Genetics and Models, 2nd ed. London, UK: Elsevier Inc. Chapter 1. 2014.
41. Hickey PT, **Stacy M**. Movement Disorders. In: Internal Medicine Board Review. 2015.(In Press)
42. Hickey PT, **Stacy M**. Management of non-motor symptoms of Parkinson's disease. In: Jankovic, J; Parkinson's Disease: Medical and Surgical Treatment. 2015. (In press)

Books:

1. **Stacy M**. Handbook of Dystonia, Stacy M, ed. Taylor & Francis, Philadelphia. 2006.
2. **Stacy M**. Handbook of Dystonia, 2nd Edition. Stacy M, ed. Informa, Philadelphia. 2012.

Study Group publications:

1. An algorithm for the management of Parkinson's disease. Koller WC, Silver DE, Leiberma A, eds. Neurology (suppl) 1994.
2. Koller W, Busenbark K, Miner K, Essential Tremor Study Group. The Relationship of Essential Tremor to Other Movement Disorders--Report on 678 Patients. Ann Neurol 1994, 35:717-723.
3. Parkinson Study Group. A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for Parkinson's disease. Neurology 2000;54:1583-8.
4. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease, a randomized controlled trial. JAMA 2000;284:1931-8.
5. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson's disease (The TEMPO Study). Arch Neurol 2002;59:1937-43.
6. Parkinson Study Group. Linkage stratification and mutation analysis at the parkin locus identifies mutation positive Parkinson's disease. J Med Genet 2002;39:489-492.
7. Parkinson Study Group. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet 2002;71:124-35.
8. Parkinson Study Group. Heterozygosity for a mutation in the *parkin* gene leads to later onset Parkinson disease. Neurology 2003;60:796-801.
9. Parkinson Study Group. Reliability of reported age of onset for Parkinson's disease. Mov Disord, 2003;18:275-279.
10. Parkinson Study Group. Significant linkage of Parkinson disease to chromosome 2q36-37. Am J Hum Genet 2003;72:1053-1057.
11. Parkinson Study Group. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Human Molecular Genetics 2003;12:2599-608.
12. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003;60:1721-1728.
13. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-6.

Study Group publications: (continued)

14. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Levodopa and the rate of progression of Parkinson disease, the ELLDOPA study. *N Eng J Med* 2004;351:2498-508.
15. Parkinson Study Group. Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations. *Mov Disord* 2004;19:22-8.
16. Parkinson Study Group. Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. *Mov Disord* 2004;19(6):649-655.
17. Parkinson Study Group. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. *Neurology* 2004;62:330-332.
18. Parkinson Study Group. Genes influencing Parkinson disease onset: replication of PARK3 and identification of novel loci. *Neurology* 2004;62:1616-1618.
19. Parkinson Study Group (Schwid S, primary author). A randomized placebo-controlled trial of rasagiline in levodopa-treated Parkinson's disease patients with motor fluctuations (The PRESTO Study). *Arch Neurol* 2005;62:241-248.
20. Parkinson Study Group-PROGENI investigators. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. *Lancet* 2005;365:410-412.
21. Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. *Neurol* 2005;65:1423-9.
22. Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K; NET-PD Investigators. A responsive outcome for Parkinson's disease neuroprotection futility studies. *Ann Neurol*. 2005;57:197-203.
23. Parkinson Study Group. Authors' response: Re-examination of the TEMPO study. *Arch Neurol* 2005;62:1320-1.
24. Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? *J Neurol* 2005;252:37-42.
25. Parkinson Study Group. Pramipexole and levodopa in early Parkinson's disease: Dynamic changes in cost effectiveness. *Pharmacoeconomics* 2005;23:1257-70.
26. Parkinson Study Group. Randomized placebo-controlled study of the nicotinic agonist SIB-1508y in Parkinson's disease. *Neurology* 2006;66:408-10.
27. Parkinson Study Group. A randomized controlled trial of Etilevodopa in Parkinson's disease patients with motor fluctuations. *Arch Neurol* 2006;63:210-6.
28. Parkinson Study Group. Rasagiline improves quality of life in early Parkinson's disease. *Mov Disord* 2006;6:16-23.
29. Parkinson Study Group. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease. *Mov Disord* 2006;21:45-9.
30. Parkinson Study Group. Safety of rasagiline in elderly Parkinson's disease patients. *Neurology* 2006;66:1427-9.
31. Parkinson Study Group. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. *J Neurol Sci*. 2006 Jul 6; [Epub]
32. Parkinson Study Group-PROGENI Investigators. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. *Mov Disord* 2006;21:45-9.
33. Parkinson Study Group TEMPO and PRESTO Tyramine Substudy Investigators and Coordinators. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. *Mov Disord* 2006;21:1716-21.
34. Parkinson Study Group-PROGENI Investigators. Mutations in LRRK2 other than G2019S are rare in the North American-based sample of familial Parkinson disease. *Mov Disord* 2006;21:2257-60.
35. Parkinson Study Group-PROGENI Investigators. Mutations in DJ-1 are rare in familial Parkinson disease. *Neuroscience Letters* 2006;408:209-13.
36. Parkinson Study Group-PROGENI Investigators. R1514Q substitution in LRRK2 is not a pathogenic Parkinson's disease mutation. *Mov Disord* 2007;22:254-7.

Study Group publications: (continued)

37. Lewitt, PA, Lyons KE, Pahwa R: SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. *Neurology*. 2007 Apr 17;68(16):1262-7.
38. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J for the SP 512 Study Group. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson's disease. *Neurology* 2007;68:272-6.
39. Jankovic J, Watts RL, Martin W, Boroojerdi B, for the SP512 Study Group. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. *Arch Neurol*. 2007 May;64(5):676-82.
40. Parkinson Study Group-PROGENI Investigators. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. *Neurology* 2007;69:1737-44.
41. Parkinson Study Group (Tanner CM, primary author). Pramipexole in levodopa-treated Parkinson disease patients of African, Asian and Hispanic heritage. *Clinical Neuropharmacol* 2007;30:72-85.
42. Parkinson Study Group-CALM-PD Investigators. Impact of pramipexole on the onset of levodopa related dyskinesias. *Mov Disord* 2007;22:1317-9.
43. Parkinson Study Group- CALM-PD Investigators. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. *Neurology* 2007;69:187-95.
44. Parkinson Study Group-CALM-PD Investigators. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. *Arch Neurol* 2007;63:1756-60.
45. Parkinson Study Group. Serum urate as a predictor of clinical and radiographic progression in Parkinson's disease. *Arch Neurol* 2008;65:716-23.
46. Parkinson Study Group. Fatigue in levodopa-naïve subjects with Parkinson's disease. *Neurology* 2008;71:481-5.
47. Parkinson Study Group. Clinical correlates of depressive symptoms in familial Parkinson's disease. *Mov Disord* 2008;23:2216-23.
48. Parkinson Study Group PRECEPT Investigators. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. *Arch Neurol* 2008;65:716-23.
49. Parkinson Study Group DATATOP and PRECEPT investigators. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. *Mov Disord*. 2009 Dec 15;24(16):2370-8.
50. Parkinson Study Group. Genomewide association study for susceptibility genes contribution to familial Parkinson's disease. *Hum Genet* 2009;124:593-605.
51. Parkinson Study Group-PROGENI Investigators. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. *Neurology* 2009;72:310-6.
52. Parkinson Study Group DATATOP Investigators. Urate as a predictor of the rate of clinical decline in Parkinson's disease. *Arch Neurol* 2009;66:1460-8.
53. Parkinson Study Group DATATOP and PRECEPT investigators. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. *Mov Disord* 2009;24:2370-8.
54. TEMPO Open-label Study Group. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. *Mov Disord* 2009;24:564-73
55. Parkinson Study Group-PROGENI Investigators. Variation in GIGYF2 is not associated with Parkinson disease. *Neurology* 2009;72:1886-92.
56. Parkinson Study Group-PROGENI Investigators. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. *Neurology* 2009;73:279-86.
57. PROGENI Investigators, Coordinators and Molecular Genetic Laboratories; GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Genomewide association study for onset age in Parkinson disease. *BMC Med Genet* 2009;10:98.
58. Parkinson Study Group PRECEPT Investigators. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. *Mov Disord*. 2010;25:1801-8.
59. Istradefylline 6002-US-007 Study Group. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. *Parkinsonism Relat Disord* 2010;16:423-6.

Study Group publications: (continued)

60. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. *Ann Neurol*. 2010;68:18-27.
61. Parkinson Study Group-PROGENI Investigators. Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. *BMC Med Genet* 2010;11:53.
62. Parkinson Study Group DATATOP and PRECEPT investigators. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. *Mov Disord* 2011;26:608-13.
63. Parkinson Study Group-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Copy number variation in familial Parkinson disease. *PLoS One* 2011;6:e20988.
64. PD GWAS Consortium. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. *Ann Neurol* 2012;71:370-84.
65. Lew MF, Somogyi M, McCague K, Welsh M; Lce QoL Study Group. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off. *Int J Neurosci* 2011;121:605-13.
66. Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, Halter C, Doheny KF, Gusella JF, Nichols WC, Myers RH, Foroud T, DeStefano AL; PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Copy number variation in familial Parkinson disease. *PLoS One* 2011;6(8):e20988.
67. Parkinson Study Group DATATOP and PRECEPT investigators. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. *Mov Disord* 2011;26:608-13.
68. Elm JJ; NINDS NET-PD Investigators. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. *Mov Disord* 2012;27:1513-21.
69. Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF; CD 140 Study Group. Efficacy, tolerability, and immunogenicity of onabotulinumtoxinA in a randomized, double-blind, placebo-controlled trial for cervical dystonia. *Clin Neuropharmacol* 2012;35:208-14.
70. The Parkinson Study Group SURE-PD Investigators, Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease: A Randomized Clinical Trial. *JAMA Neurol*. 2013 Dec 23. doi:10.1001/jamaneurol.2013.5528. [Epub ahead of print] PubMed PMID: 24366103.
71. Parkinson Study Group QE3 Investigators. A randomized clinical trial of high-dosage coenzyme q10 in early Parkinson disease: no evidence of benefit. *JAMA Neurol*. 2014;71(5):543-52. doi: 10.1001/jamaneurol.2014.131. PubMed PMID: 24664227.
72. NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators.. Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1. *JAMA Neurol*. 2016 Mar;73(3):321-8. doi: 10.1001/jamaneurol.2015.4265. PubMed PMID: 26751506.
73. CALM-PD Parkinson Study Group Investigators.. Orthostatic hypotension predicts motor decline in early Parkinson disease. *Parkinsonism Relat Disord*. 2016 Nov;32:127-129. doi: 10.1016/j.parkreldis.2016.09.011. PubMed PMID: 27639815; PubMed Central PMCID:PMC5114666.

Other Manuscripts:

1. **Stacy M**, Jankovic J. Parkinson's Disease and Disorders of Communication. *Neurospeech Newsletter* 1991;6:1.
2. **Stacy M**. Treatment of Severe Motor Fluctuations in Parkinson's Disease. American Academy of Family Physicians 45th Annual Meeting, San Diego, CA. Course #307. 1992.
3. **Stacy M**. Recognition and Treatment of Parkinson's Disease and other Tremor disorders. American Academy of Family Physicians 47th Annual Meeting, Boston, MA. Course #307. 1994.
4. York D, **Stacy M**. The Man with a Shaking Hand. University of Missouri Problem Based Learning Curriculum. 1994.

Other Manuscripts: (continued)

5. **Stacy M**, Farmer J, Spollen L. Forgetfulness. University of Missouri Problem Based Learning Curriculum. 1995.
6. **Stacy M**. Medications Used in Parkinson's Disease. Missouri Academy of Family Physicians 47th Annual Meeting. pp. 139-144. 1995.
7. **Stacy M**. Medical Management of Parkinson's Disease. Gold Pharmacy Newsletter. 1995.
8. **Stacy M**. An Algorithm for Introducing Medications in Parkinson's Disease. Athena Neurosciences, 1996.
9. **Stacy M**. Symptom Management in Parkinson's Disease. Parkinson Post. San Diego Parkinson Corporation. 1996.
10. **Stacy M**. Treatment of the Advancing Parkinson's Disease Patient. American Academy of Family Physicians 49th Annual Meeting, New Orleans, LA, 1996.
11. **Stacy M**. Symptom Management in Parkinson's Disease. Parkinson Report. National Parkinson Foundation. 1997.
12. **Stacy M**. Dystonia and Parkinson's disease. Arizona Parkinson Report. Spring 1997.
13. **Stacy M**. Activities of Daily Living in Parkinsonism. Capitol Parkinson Report. Fall 1997.
14. **Stacy M**. Activities of Daily Living Scales in Parkinson's Disease Research. Capitol Parkinson Report. 1997.
15. Carmody J, **Stacy M**. Etiology of Parkinson's Disease. DuPont Pharma Internal Publication. 1997.
16. Carmody J, **Stacy M**. Pathogenesis of Parkinson's Disease. DuPont Pharma Internal Publication. 1997.
17. **Stacy M**. Recognition and Treatment of non-motor symptoms in Parkinson's disease. Southwest Parkinson Report. 1998.
18. **Stacy M**. Parkinson's Disease: More Than Just a Movement Disorder. Southwest Parkinson Report. 1998.
19. **Stacy M**. Botulinum Toxin Injection Techniques for Blepharospasm. Benign Essential Blepharospasm Research Foundation Newsletter 2000
20. **Stacy M**. Choosing the Right Doctor. Dystonia Dialogue. 2003
21. **Stacy M**. Identifying Wearing-Off In Parkinson's Disease. European Parkinson's Disease Association Newsletter. 2004
22. **Stacy M**. Special Specs in Blepharospasm. Benign Essential Blepharospasm Research Foundation Newsletter 2006;25(1):1,4.
23. **Stacy M**. Is Blepharospasm a Neurological Disorder? Benign Essential Blepharospasm Research Foundation Newsletter 2006;25(3):1,3-4.
24. **Stacy M**. Everything you wanted to know about blepharospasm, but were afraid to ask. Benign Essential Blepharospasm Research Foundation Newsletter 2008
25. **Stacy M**. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia. Focus on Parkinson's Disease 2008;20:17-20.
26. **Stacy M**, Hickey, PT. Injection Techniques with Botulinum Toxin In the Treatment of Blepharospasm. *Benign Essential Blepharospasm Research Foundation*. 2011. Provider Handout.
27. **Stacy M**. The Impact of the BEBRF: 1980 – 2015. Where do we go from here? *Benign Essential Blepharospasm Research Foundation*. 2015

Selected Abstracts:

1. Logue MB, **Stacy M**, Bell-Dolan DJ. Psychopathology in an Outpatient Sample of Children and Adolescents with Tourette Syndrome. 1994 Association for the Advancement of Behavior Therapy Annual Convention.
2. Childers MK, **Stacy M**, Eissler D, Biederman R, Petroski GF, Stonnington HH, Rupright J. Predictors of contracture in traumatic brain injury. American Society of Rehabilitation, 1993.
3. Boote E, Theiss T, **Stacy M**. A Proton MRS Study of Multiple Sclerosis Patients with Correlation to Clinical Disability and Duration of Time since Diagnosis. 1995 AAPM Meeting.

Selected Abstracts: (continued)

4. Cooke DL, **Stacy M**, Batchu S. Beta-Interferon in the Treatment of Multiple Sclerosis: Effects on Functional Balance. WCPT Congress Scientific Program, American Physical Therapy Association. 1995
5. **Stacy M**. Treatment of the Early Parkinson's Disease Patient. Parkinson/Alzheimer Disease Digest. 1996.
6. **Stacy M**, Kurth MC, Woolhieser D. Olanzapine in the Treatment of Tardive Dyskinesia. American Neurological Association, 1997.
7. Samanta J, **Stacy M**. Quetiapine in the Treatment of Hallucinations in Parkinson's Disease. Fourth International Congress of Movement Disorders, 1998.
8. Brewer M, **Stacy M**. Sildenafil citrate in the Treatment of Sexual Dysfunction in Parkinson's Disease American Neurological Association, 1998.
9. Comella CL, Siemers ER, Goetz CG, Leurgans S, Stebbins GT, and the Dystonia Study Group. Development of the Unified Dystonia Rating Scale: assessment of reliability. Presented at the 50th Annual Meeting of the American Academy of Neurology, Minneapolis, Minn April 28, 1998. Neurology 1998; 550 (supp 4): A70.
10. Parkinson Study Group. The glutamate antagonist remacemide improves motor performance in levodopa-treated Parkinson's disease. Presented at the 51st Annual Meeting of the American Academy of Neurology, Toronto, Canada. April 1999. Neurology 1999; 52 (suppl 2): A293.
11. Comella CL, Leurgans S, Chmura TA, and the Dystonia Study Group. The Unified Dystonia Rating Scale: initial concurrent validity testing with other dystonia scales. Presented at the 51st Annual Meeting of the American Academy of Neurology, Toronto, Canada. Neurology 1999;52(suppl 2):A293
12. Baev K, Greene K, Lieberman A, Lou J-S, Marciano F, Shetter A, **Stacy M**, Spetzler R. The Basal Ganglia and Functional Neurosurgical Procedures in Motor Disorders: Practical and Theoretical Aspects, 1999.
13. Hauser RA, Comella C, Brashear A, Truong, D, Charles D, Tsui J, 140 Study Group, Mordaunt J, Nordquist M, Bugarin D, Jenkins S. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Original Botox (botulinum toxin type A) Purified Neurotoxin Complex for the Treatment of Cervical Dystonia. International Conference: Basic & Therapeutic Aspects of Botulinum & Tetanus Toxins, 1999.
14. Blindauer K and the Parkinson Study Group. Double-blind, placebo-controlled, dose-ranging study of the safety and tolerability of SIB-1508Y, a nicotinic receptor agonist, in early Parkinson's disease patients. Neurology, 2000;54:A278.
15. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson's disease. Ann Neurol 2000;48:489.
16. Holloway R, and the Parkinson Study Group. Pramipexole versus Levodopa in Early Parkinson's disease: A randomized clinical trial. Presented at the 52nd Annual Meeting of the American Academy of Neurology, San Diego, CA. April 29-May 6, 2000. Neurology 2000; 54(suppl 3):A89.
17. Marek KL and the Parkinson Study Group. B-CIT/SPECT assessment of progression of Parkinson's disease in subjects participating in the CALM-PD study. Presented at the 52nd Annual Meeting of the American Academy of Neurology, San Diego, CA. Neurology 2000;54(suppl 3):A90.
18. Dystonia Study Group. Axial and cranial dystonia: Inter-rater agreement on presence of dystonia using a standardized videotape assessment. Presented at the 14th Annual Symposia of Etiology, Pathogenesis and Treatment of Parkinson's disease and other Movement Disorders. Mov Disord 2000;15:1043.
19. Samanta J, **Stacy M**. Compulsive Gambling in Dopaminergic Therapy in Parkinson's Disease. 6th International Congress of Parkinson's Disease and Movement Disorders, 2000.
20. Mahant P, **Stacy M**, Sivakumar K. Treatment of Hereditary Geniospasm with Botulinum Toxin. 6th International Congress of Parkinson's Disease and Movement Disorders, 2000.

Selected Abstracts: (continued)

21. **Stacy M**, Drumm D, Samanta J, Williamson K, Mahant P, Shetter A. Deep Brain Stimulation of the Subthalamic Nucleus for the Treatment of Parkinson's Disease. 125th Annual Meeting of the American Neurological Association, 2000.
22. Kittle G, Oblas B, Okun M, **Stacy M**. Stress and Coping in Caregivers of Spouses with Parkinson's Disease. 6th International Congress of Parkinson's Disease and Movement Disorders, 2000.
23. Hauser R, Reider C, **Stacy M**, Hubble J, Seeberger L, Gauger L, Williamson K, Dingmann C, Rice R, Krulewicz S, Zaninelli R. Acute versus gradual pramipexole to ropinirole switch. 6th International Congress of Parkinson's Disease and Movement Disorders, 2000.
24. Dystonia Study Group. Axial and cranial dystonia: Inter-rater agreement on presence of dystonia using a standardized videotape assessment. Presented at the 14th Annual Symposia of Etiology, Pathogenesis and Treatment of Parkinson's disease and other Movement Disorders. *Mov Disord* 2000;15:1043.
25. Samanta J, **Stacy M**. Efficacy of botulinum toxin type B (Myobloc™) in a case of hemifacial spasm. 7th International Congress of Parkinson's Disease and Movement Disorders, 2002.
26. Samanta J, **Stacy M**. Efficacy of botulinum toxin type B (Myobloc™) for treatment of blepharospasm: report of two cases. 7th International Congress of Parkinson's Disease and Movement Disorders, 2002.
27. **Stacy M**, Hauser R, Samanta J, Zesiewicz T, Sebade D, Cimino C. The Total Functional Capacity Scale: a useful and rapid assessment tool for monitoring Parkinson's disease disability. 7th International Congress of Parkinson's Disease and Movement Disorders, 2002.
28. **Stacy M**. Treatment of limb dystonia with botulinum toxin – type B. 7th International Congress of Parkinson's Disease and Movement Disorders, 2002.
29. Thomas K, Samanta J, Mahant P, Williamson K, **Stacy M**. The Ali Project: a web-based database for Parkinson's disease. 7th International Congress of Parkinson's Disease and Movement Disorders, 2002.
30. **Stacy, M** on behalf of the EODWO Working Group. Wearing-Off in Parkinson's disease: A Patient Survey vs. Programmed Clinic Evaluation. 17th Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders. *Mov Disord* 2003;9:1094.
31. **Stacy M** on behalf of the EODWO Working Group. End-of-Dose Wearing-off in Parkinson's Disease: Sensitivity Comparison of a Patient Survey versus a Programmed Investigator Evaluation. European Federation of Neurological Sciences, 2003.
32. Parkinson Study Group. Does Levodopa slow or hasten the rate of progression of Parkinson's disease? The results of the ELLDOPA Trial. Presented at the 55th Annual Meeting of the American Academy of Neurology, Honolulu, Hawaii. *Neurology* 2003; 60: A80-1.
33. Blindauer K and the Parkinson Study Group. Delayed response to Levodopa and response failures account for a large percentage of daily off time in advanced Parkinson's disease patients with motor fluctuations. Presented at the 55th Annual Meeting to the American Academy of Neurology, Honolulu, Hawaii. *Neurology* 2003; 60: A81-A82.
34. Marek K, Seibyl J, Jennings D, and the Parkinson Study Group. Pramipexole versus Levodopa: 5-year follow-up of Parkinson disease progression assessed by dopamine transporter imaging in the CALM-PD CIT study. Presented at the 55th Annual Meeting of the American Academy of Neurology, Honolulu, Hawaii. *Neurology* 2003;60:A293.
35. Fahn S and the Parkinson Study Group. Evaluation and long-duration benefit from levodopa: Results from the ELLDOPA (earlier vs later) study. 17th Annual Symposia on the Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. 2003;18;1085-6.
36. GPI 1485 Trial Group. A 2-year randomized, placebo-controlled trial of the neuroimmunophilin ligand, GPI 1485, on dopamine transporter density and disease progression. Design and patient baseline characteristics. 18th Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders. *Mov Disord* 2004;19 (suppl 9):S175-6.

Selected Abstracts: (continued)

37. LeWitt PA, US-005/006 Clinical Investigator Group. "Off" time reduction from adjunctive use of istradefylline (KW-6002) in levodopa-treated patients with advanced Parkinson's disease. 18th Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders. *Mov Disord* 2004;19 (suppl 9):S222.
38. Comella C, Jankovic J, Leurgans S, Fan W, Chmura T, Dystonia Study Group. Botulinum toxin serotype A compared to B in cervical dystonia: randomized, double-blind, parallel study. 129th Annual American Neurological Association. *Ann Neurol* 2004;56:S25.
39. Biglan KM, Holloway RG, McDermott MP, Richard IH, Parkinson Study Group. Predicting incident non-motor complications of dopaminergic therapy in patients with early Parkinson's disease: A secondary analysis of the CALM-PD trial. *Mov Disord* 2004;19 (Suppl 9):S205.
40. Parkinson Study Group (Elmer L, presenter). Rasagiline improves symptoms in Parkinson's disease (PD) without worsening cognitive and behavioral symptoms. Congress on Mental Dysfunctions in Parkinson's Disease, Salzburg, October 2004.
41. Adler CA, Caviness JN, Sabbagh M, Connor D, Hentz JG, Shill H, Evidente VGH, **Stacy M**, Joyce J, Beach T. Motor Impairment in Normal Aging, Possible PD, and Definite PD: Longitudinal Evaluation of a Cohort of Prospective Brain Donors. 18th Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders, 2004.
42. Jankovic J, Ondo WG, **Stacy MA**, Pawha R, Elble RJ, Hulihan JF, Schwarzman L, Wu S-C and the Essential Tremor Study Group. A multicenter, double-blind, placebo-controlled trial of topiramate in essential tremor. American Academy of Neurology, 2004.
43. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Hutchinson M, Kelly P, Dalvi A, Scott B, **Stacy M**, Turner D, Wooten VGF, Elias WJ, Laws ER, Dhawan V, Stoessl AJ, Matcham J, Coffey RJ, Traub M. Multicenter, double-blind, randomized, placebo-controlled, Phase 1/2 trial (RCT) of bilateral intraputamenal (lpu) infusion of glial cell line-derived Neurotrophic factor (GDNF) in Levodopa-responsive Parkinson's disease (PD): preliminary results. American Academy of Neurology, 2004.
44. **Stacy M** on behalf of the EODWO group. End of dosing wearing-off (EODWO): patient questionnaire versus physician assessment – rational for the patient card as a diagnostic aid. 18th Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders, *Mov Disord* 2004.
45. **Stacy M**, US-005/006 Clinical Investigator Group. Istradefylline (KW-6002) as adjunctive therapy in patients with advanced Parkinson's disease: A positive safety profile with supporting efficacy. 18th Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders. *Mov Disord* 2004;19 (suppl 9):S215-6.
46. **Stacy M** on behalf of the EODWO working group. An abbreviated wearing-off Patient questionnaire (WOPQ-9): Sensitivity analysis. 18th International Congress of Parkinson's Disease and Movement Disorders. *Mov Disord* 2005;20(suppl 10):S117.
47. **Stacy M** on behalf of the EODWO working group. An abbreviated wearing-off Patient questionnaire (WOPQ-9): Sensitivity analysis. 16th International Conference on Parkinson's Disease and Related Disorders. Berlin 2005.
48. Rerat K, Azulay J-F, **Stacy M**, Durif F, Rogez R, Tranchant C, Bourdeix I. PRECOCE and the Ali Study: Differences in study design suggest usefulness of a new self-assessment patient card for early detection and management of Parkinson's disease fluctuations. 16th International Conference on Parkinson's Disease and Related Disorders. Berlin 2005.
49. Parkinson Study Group. Impact of pramipexole on mood and initiative in early Parkinson's disease. 8th International Congress of Parkinson's Disease and Movement Disorders. *Mov Disord* 2005;20(suppl 10):S120.
50. Parkinson Study Group. Rasagiline does not promote tyramine pressor responses. 8th International Congress of Parkinson's Disease and Movement Disorders. *Mov Disord* 2005;20(suppl 10):S132.

Selected Abstracts: (continued)

51. Parkinson Study Group. Rasagiline is effective and well tolerated in the treatment of Parkinson's disease (PD) patients with levodopa-related motor fluctuations receiving other adjunctive therapy. 8th International Congress of Parkinson's Disease and Movement Disorders. *Mov Disord* 2005;20(suppl 10):S138.
52. Parkinson Study Group, Stern M. A controlled trial of rasagiline in Parkinson's disease patients with levodopa-related motor fluctuations (PRESTO Study). *Ann Neurol* 2003;54:S27.
53. Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I, PSG TEMPO & PRESTO Investigators, et al. Safety of rasagiline in elderly Parkinson's disease (PD) patients. *Mov Disord* 2005;20 (Suppl 10):S81.
54. Kieburtz K, Romer M, McDermott M, Kamp C, Parkinson Study Group. Impact of pramipexole on mood and initiative in early Parkinson's disease. *Mov Disord* 2005;20 (Suppl 10):S121.
55. Parkinson Study Group (Elmer L, presenter). Rasagiline is effective and well tolerated in the treatment of Parkinson's disease (PD) patients with levodopa-related motor fluctuations receiving concomitant dopamine agonist (DA) therapy. *Annals Neurol* 2005;58(Suppl 9):S54.
56. Parkinson Study Group (Schwid SR, presenter). Safety of rasagiline in combination with serotonin reuptake inhibitors. *Annals Neurol* 2005;58(Suppl 9):S56.
57. Parkinson Study Group (Schwid S, presenter). A randomized controlled trial of etilevodopa in Parkinson's disease patients with motor fluctuations. *Mov Disord* 2005;20(9):1237.
58. BOS Research Group. Botulinum Type B Observational Study. 8th International Congress of Parkinson's Disease and Movement Disorders, Rome, 2005.
59. Parkinson Study Group—PROGENI Investigators. A common non-synonymous SNP in the BR13 (ITM2C) gene accounts for a significant portion of the linkage evidence for Parkinson disease on chromosome 2q. Presented at The American Society of Human Genetics, October 25-29, 2005, Salt Lake City, UT. Available from: <http://www.ashg.org/cgi-bin/ashg05s/ashg05>
60. Truong D for the Dysport Blepharospasm Study Group. Efficacy and safety of botulinum toxin, type A (Dysport) for the treatment of benign essential blepharospasm. 16th International Conference on Parkinson's Disease and Related Disorders. Berlin 2005.
61. Kieburtz K, Romer M, McDermott M, Kamp C and the CALM-PD Parkinson Study Group Investigators. Impact of pramipexole on the onset of levodopa-related dyskinesias. *Mov Disord* 2006;21(Suppl 13):S122.
62. Parkinson Study Group (Tanner CM, presenter). Follow-Up of persons with Neurologic Disease (FOUND): Up to 46 months follow-up. *Mov Disord* 2006;21(Suppl 13):S127.
63. Shoulson I and Parkinson Study Group (PSG) PRECEPT Investigators. CEP-1347 treatment fails to favorably modify the progression of Parkinson's disease (PRECEPT) study. *Neurology* 2006;67(1):185.
64. Parkinson Study Group—PROGENI Investigators. Mutations in LRRK2 other than G2019S are rare in familial Parkinson disease. Presented at The American Society of Human Genetics, October 9-13, 2006, New Orleans, LA.
65. The Parkinson Study Group—PROGENI Investigators. R1514Q substitution in LRRK2 is not a pathogenic Parkinson disease (PD) mutation. Presented at The American Society of Human Genetics, October 9-13, 2006, New Orleans, LA.
66. Marek K, Tabamo R, Jennings D, Seibyl JP and the INSPECT Study Group. An investigation of the effects of short-term treatment with pramipexole of levodopa on [¹²³I]-β-CIT and SPECT imaging in early Parkinson's disease. American Academy of Neurology, 2006.
67. Koller WJ, **Stacy M**. Apomorphine as a Diagnostic Tool for Parkinson's Disease. World Parkinson Congress February 22–26, 2006. Poster 132
68. **Stacy M**, Spears JB, Van Lunen BE. Implications of Motor Fluctuations in Parkinson's Patients on Chronic Therapy (IMPACT): Comparison of Patient- and Physician-Reported Data. World Parkinson Congress, 2006. Poster 133

Selected Abstracts: (continued)

69. **Stacy M**, Jim Wang J, Koumaras B, Gunay I. COMPASS 1: A study to assess the sensitivity and specificity of the Wearing-off Questionnaire – 9 Item (WOQ-9). American Neurological Association, 2006.
70. **Stacy M**, Sethi KD, Earl NL. Ropinirole 24-Hour Prolonged Release Improves Sleep but Does Not Increase Daytime Sleepiness when Used as Adjunctive Therapy in Patients with Parkinson's Disease Not Optimally Controlled by L-Dopa. 20th Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders, 2006.
71. Vornov J, Seibyl J, **Stacy M**, Weiner W and Marek K for The GPI Investigator Group. GPI 1485, a Neuroimmunophilin Ligand, Fails to Alter Disease Progression in Mild to Moderate Parkinson Disease. 9th International Congress of Parkinson's Disease and Movement Disorders, Istanbul 2006.
72. Stocchi F, **Stacy MA**, Giorgi L, Earl N. Safety and Tolerability of ropinirole 24-hour prolonged release as adjunctive therapy in patients with Parkinson's disease. European Federation of Neurological Societies, Glasgow, 2006.
73. Pawha R, Stocchi F, **Stacy M**. Ropinirole 24-hour prolonged release is effective in sparing L-dopa dose and improving symptoms as adjunctive therapy in Parkinson's Disease. European Federation of Neurological Societies, Glasgow, 2006.
74. Kulkarni AS, **Stacy MA**, Balkrishnan R, Kirsch J, Edin HM. Prevalence of non-adherence to Parkinson's Disease medications in an elderly population. European Federation of Neurological Societies, Glasgow, 2006.
75. Pawha R, Stocchi F, **Stacy MA**. Ropinirole 24-hour prolonged release is effective in sparing L-dopa dose and improving symptoms as adjunctive therapy in Parkinson's Disease. AAN 2006.
76. Kulkarni AS, **Stacy MA**, Balkrishnan R, Kirsch J, Edin HM. Relation between adherence to PD medications and symptom progression in an elderly population. European Federation of Neurological Societies, Glasgow, 2006.
77. Pahwa R, **Stacy MA**, Elmer L, Isaacson SH. Ropinirole 24-hour prolonged release provides efficacy as early as Week 2 when used as adjunctive therapy to L-dopa in patients with advanced Parkinson's disease. 10th International Congress of Parkinson's Disease and Movement Disorders, Kyoto, Japan, 2006.
78. **Stacy M**, Pahwa R, Earl N, Colcher A. Ropinirole 24-hour prolonged release reduces 'off' time and reduces the need for L-dopa when used as adjunctive therapy in patients with advanced Parkinson's disease. 10th International Congress of Parkinson's Disease and Movement Disorders, Kyoto, Japan, 2006.
79. Delea T, Hagiwara M, Thomas SK, Mancione L, Kakarieka A, **Stacy M**. Compliance with Levodopa/Carbidopa/Entacapone (L/C/E) as a Fixed Dose Combination (FDC) versus Levodopa/Carbidopa plus Entacapone (L/C + E) in Parkinson's Disease. 10th International Congress of Parkinson's Disease and Movement Disorders, Kyoto, Japan, 2006.
80. Stacy M for the COMPASS I Study Group. COMPASS 1: A study to assess the sensitivity and specificity of the Wearing-off Questionnaire – 9 Item (WOQ-9). American Neurological Association, Chicago 2006.
81. Wingo TS, Evatt M, Scott B, Freeman A, Stacy M. Impulse control disorders arising in three patients treated with rotigotine. Impulse Control Disorders in Parkinson's Disease, Toronto 2007.
82. Delea T, Thomas S, Hagiwara M, **Stacy M**. Improved compliance with levodopa/carbidopa/entacapone (Stalevo®) or levodopa/carbidopa and entacapone as separate tablets reduces medical care utilization and costs among patients with Parkinson's disease. World Federation of Neurology 2007.
83. Murck H, **Stacy M**, Koumaris B, Meng S, Kroenke K. Is there a role of somatization in the manifestation of non-motor symptoms of Parkinson's Disease? Annual Meeting of the American Psychiatric Association, May 19-24, San Diego 2007.
84. Parkinson Study Group – PROGENI Investigators. Depression in a Cohort of 1335 Individuals with Familial Parkinson Disease. *Neurology* 2007;68(1):A37.

Selected Abstracts: (continued)

85. Biglan KM, Brocht A, McDermott M, Kieburtz K, Parkinson Study Group CALM-PD Investigators. Identifying predictors of somnolence and edema in patients with early Parkinson's disease treated with pramipexole: A secondary analysis of the CALM-PD study. *Mov Disord* 2007;22(16):S231.
86. Biglan KM, Brocht A, McDermott M, Kieburtz K, Parkinson Study Group CALM-PD Investigators. Identifying predictors of response to pramipexole treatment in early Parkinson's disease: A secondary analysis of the CALM-PD study. *Mov Disord* 2007;22(16):S232.
87. Elble R for the Tremor Research Group (TRG). The Essential Tremor Rating Assessment Scale (TETRAS). 11th International Congress of Parkinson's Disease and Movement Disorders, Chicago 2008.
88. Weintraub D, Koester J, Potenza MN, Siderowf AD, **Stacy MA**, Whetteckey J, MD, Wunderlich GR, Lang, AE for the DOMINION Study Group. Dopaminergic Therapy and Impulse Control Disorders in Parkinson's Disease: A Cross-Sectional Study of Over 3,000 Patients. 11th International Congress of Parkinson's Disease and Movement Disorders, Chicago 2008.
89. Voon V, Koester J, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, Weintraub D, Wunderlich GR, **Stacy M**. Factors associated with impulse control disorders in Parkinson's disease: a case control study of 584 subjects. American Academy of Neurology, Seattle 2009.
90. **Stacy M**, McCague K, Weidenman M, Campbell A, Somogyi M. A Randomized, Double-Blind Evaluation of Levodopa/Carbidopa/Entacapone Versus Immediate-Release Levodopa/Carbidopa in Patients With Parkinson's Disease Exhibiting Non-Motor Symptoms of Wearing Off. American Academy of Neurology, Seattle 2009.
91. Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, **Stacy M**, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, Kordower JH, Olanow CW. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. *World Federation of Neurology*, 2009
92. Jankovic J, Charles D, Comella CL, **Stacy M**, Adler CH, Misell LM, Kurth M, Manasee V Shah BMV, Brin MK, Boo LM. CD-PROBE (**C**ervical **D**ystonia **P**atient **R**egistry for **O**bservation of **B**OTOX® **E**fficacy) — A Multicenter, Observational Study of Repeated Botulinum Toxin Type-A Injections in Cervical Dystonia (CD) Patients – Preliminary Baseline Data. American Academy of Neurology, Toronto 2010.
93. Charles D, Adler CH, Comella CL, Jankovic J, **Stacy M**, Kurth M, Brin MK, Boo LM. CD-PROBE (**C**ervical **D**ystonia **P**atient **R**egistry for **O**bservation of **B**OTOX® **E**fficacy) — A Multicenter, Observational Study of OnabotulinumtoxinA Injections in Cervical Dystonia (CD) Patients – Baseline Data and Interim Patient Reported Outcome. American Association of Physical Medicine and Rehabilitation. Seattle, 2010.
94. **Stacy M**, Laliberté F, Kulkarni AS, Somogyi M, Vekeman F, Duh M-S, Lefebvre P. Compliance and persistence to single-tablet levodopa/carbidopa/entacapone compound versus levodopa/carbidopa in idiopathic Parkinson's Disease. American College of Clinical Pharmacy, Austin, TX, 2010.
95. **Stacy M**, Laliberté F, Kulkarni AS, Somogyi M, Vekeman F, Duh M-S, Lefebvre P. Impact of levodopa/carbidopa/entacapone compound versus levodopa/carbidopa on hospitalization rates in patients with idiopathic Parkinson's Disease. American College of Clinical Pharmacy, Austin, TX, 2010.
96. Barone P, Fernandez H, Ferreira JJ, Müller T, Saint-Hilaire M, **Stacy M**, Tolosa E, von Raison F, Kenney C, Musch B. Study design of MOTION: a 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide in early Parkinson's disease. European Federation of Neurological Societies, Geneva 2010.
97. Hattori N, Fujimoto K, Kondo T, Murata M, **Stacy M**. Patient Perspectives towards levodopa therapy in Japan and the United States - results of two patient surveys. World Parkinson Congress, Glasgow 2010.

Selected Abstracts: (continued)

98. Stocchi F, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Rascol O, **Stacy M**, Tolosa E, Trenkwalder C, Gao H, Nagel J, Gomez-Mancilla B, Merschhemke M, Tekin S, Abi-Saab W. A 13-week, double-blind, placebo-controlled study of AFQ056, a metabotropic glutamate receptor 5 antagonist in Parkinson's disease patients with moderate-to-severe L-dopa induced dyskinesias. Movement Disorders Society, Buenos Aires, 2011.
99. Jankovic J, **Stacy M**, Charles D, Adler C, Brin M, Papapetropoulos S, and the CD PROBE Study Group. Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE): Interim Results of Physician- and Patient-Reported Outcomes. International Dystonia Symposium, 2011
100. Siffert J, **Stacy M**, Turner D, Tagliati M, Alterman R, Factor S, Boulis N, Olanow CW, Lang AE, Lozano A, Bartus RT. Safety and Feasibility of Intranigral and Intraputaminial CERE-120 (AAV2-neurturin) administration in Parkinson's Disease. Movement Disorders Society, Dublin, 2012.
101. Molho ES, **Stacy M**, Gillard P, Charles D, Adler CH, Jankovic J, Schwartz M, Brin MF. Cervical Dystonia and Work Productivity: Results From the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE). Parkinson's Disease and Movement Disorders 2015
102. Hickey PT, Kuchibhatla M, Scott B, Gauger L, **Stacy M**. Assessment of outcomes in Parkinson's disease subjects randomized to SPECT imaging of the dopamine transporter. Parkinson Study Group 2015
103. Nagler A, Rudd M, Snyder D, Tiemann H, Bixby P, Kuhn C, **Stacy M**. Building a Research Foundation: A Collaborative, Institution-Wide Initiative for Medical Education Learners. American Association of Medical Colleges 2015
104. Adler C, Charles D, Jankovic J, Comella C, **Stacy M**, Schwartz M, Adams AM, Brin MF. Treatment Patterns and Patient Disposition in the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE). American Academy of Neurology 2015
105. Morgan J, **Stacy M**, Rubens R, Khannn S, Gupta S. Dosing patterns during conversion to IPX066, extended-release carbidopa-levodopa, from other carbidopa-levodopa formulations in advanced Parkinson's disease patients. American Academy of Neurology, 2016
106. **Stacy M**, Biton V, Aldred J, Ellenbogen A, Rubens R, Modi NB, Mittur A, Khanna S, Gupta S. Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson's disease: A single-dose Phase 2 study. Movement Disorders Society, 2017.
107. Factor S, **Stacy M**, Burke J, Yonan C, Le H, Liang GS. Abnormal Movements by Body Region in Subjects with Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Mood Disorder: Findings from the KINECT 3 Study. Movement Disorders Society, 2017.
108. **Stacy M**, Kurlan R, Burke J, Siegert S, Liang GS, O'Brien CF. A Potential MCID for AIMS Dyskinesia Total Score Change in Subjects with Tardive Dyskinesia. Movement Disorders Society, 2017.

Editorials, position, and background papers:

1. **Stacy M**, Lou J-S. Editorial: Treatment Options in Parkinson's Disease. CNS Spectrums 1998;3:22.
2. **Stacy M**, Factor S. Rapid Treatment of "Off" episodes: Will this change Parkinson's disease therapy? Neurology 2004;62 (suppl):S2-3.
3. **Stacy M**. Editorial Commentary. The value of post-marketing medication surveys in Parkinson's disease. Current Med Res Opin 2004;20;113-4.
4. Lang AE, Langston W, Lozano A, Moro E, Nutt J, **Stacy M**, Stoessl J, Turner D, Wooten GF. The Hard Way to a Bill of Rights. Lancet Neurology 2006;5:200-2.
5. **Stacy M**. Should GDNF intraparenchymal trials be continued? NO. Moving Along. 2007
6. **Stacy M**. Faculty Member for *Faculty of 1000 Medicine* ISSN Online: 1740-309X. 2008
7. Barker RA, **Stacy M**, Brundin P. A new approach to disease-modifying drug trials in Parkinson's disease. J Clin Invest. 2013 May 20:1-2.

Professional awards and special recognitions:

Duke University, School of Medicine Distinguished Faculty	2017
Member, Alpha Omega Alpha	2016
Fellow, American Neurological Association	2012
Alumni Merit Award, College of Science and Mathematics Southeast Missouri State University	2011
Member, American Neurological Association	2006
Fellow, American Academy of Neurology	2005
Best Doctors in North Carolina	2004 – present
The Outstanding Young Physician Award University of Missouri, School of Medicine	2003
Best Doctors in Phoenix	2002
Best Doctors in America	2001
Dystonia Medical Research Foundation, Doctor of Excellence	2000
Outstanding Resident Teaching Award University of Missouri, Division of Neurology	1996
Outstanding Young Alumni, Southeast Missouri State University	1995
Excellence in Education Award, Student Affairs Council, University of Missouri	1992

State Licensure:

North Carolina	200300890	2003 (active)
Arizona	24390	1996
California	C050086	1997
Missouri	MD36827	1986
Nevada	8097	1997
Pennsylvania	MD-042235-e	1988
Texas	H8848	1990

Organizations and participation:

World Parkinson Congress, Steering Committee	2019
Co-Chair, Fundraising Committee	
Parkinson's Disease and Movement Disorder Society	2016
Strategic Planning Committee, Pan-American Chapter	
Parkinson's Disease and Movement Disorder Society	2016
Strategic Planning Committee, International Executive Committee	
World Parkinson Congress, Steering Committee	2016
Co-Chair, Fundraising Committee	
Brain Foundation Netherlands, Grant Reviewer	2015
World Health Organization: Parkinson's Disease Working Group	2009
World Congress on Parkinson's Disease and Related Disorders	2009
Abstract Review Committee	
Mental Dysfunction and Gait Disorders, 6th International Congress	2008
Scientific Advisory Board	
Neuroimaging in Parkinson's and Related Disorders, 2 nd International Congress	2008
International Program Committee	
Impulse Control Disorders in Parkinson's Disease, Toronto	2007
Planning Committee, Chair	

Organizations and participation: (continued)

Michael J. Fox Foundation: Grant Reviewer	2007
The Parkinson's Disease Society (United Kingdom): Grant Reviewer	2006 – 2017
American Neurological Association, Member	2006
Fellow	2012
Annual Meeting, Abstract Reviewer	2007
American Parkinson's Disease Association	
Information and Referral Center	2003 – 2004
Benign Essential Blepharospasm Research Foundation	
Symposium Chair	1999
Symposium Lecturer	1998 – 2001
Medical Advisory Board Member	2001 – present
WE MOVE	
Board Member	2002 – 2015
Dystonia Task Force Member	2000
Movement Disorder Slide Set Editor	2001
Parkinson's Disease Slide Set Editor	1999
Education Committee, Chair	1998 – 2013
Dystonia Study Group	1997 – 2017
Nominating Committee	2006
Parkinson Study Group	1997 – present
Executive Committee Member	2013 – 2017
Budget Committee, Chair	2012 – 2017
Nominating Committee	2002 – 2004
Credentials Committee	2004 – 2007
Parkinson Disease and Movement Disorders Society	1990 – present
International Executive Committee	2013 – 2017
Archives Committee	2011 – present
Moving Along (Society Newsletter), Editor	2009 – present
Publications Committee	2008 – present
Membership Committee	2004 – 2006
Industrial Relations Committee	2006 – 2008
Lecturer	2006 – 2008
Course Director	2008
American Academy of Neurology	1988 – present
Councilor, Movement Disorders Section	2008 – 2012
Fellow	2006 – present
Scientific Review Committee	2006
Invited Lecturer	2000 – 2006
Movement Disorders Satellite Course Director	2006
Liaison Committee	1997
Movement Disorders Section	1995 – 2017
National Parkinson Foundation	1996 – 2003
Duke University Center of Excellence	2008
Neurological Consultant	1996
Center Director	1996 – 2003
"Ask the Doctor"	1997 – 1999
Ad Hoc Committee; Caregivers Award	1998
Associate Medical Director	1998 – 2002
Parkinson's Disease Algorithm Committee Member	1993 – 1994

Invited Editorships:

Moving Along: A quarterly newsletter of the Parkinson's Disease and Movement Disorders Society	2009 – present
Impulse Control Disorders II; Proceedings of International Meeting, Mov Disord	2015
Impulse Control Disorders; Proceedings of International Meeting, Mov Disord	2008
Apomorphine as a Rescue Therapy for Parkinson's Disease, Neurology	2004
Essential Tremor Monograph, Clinician	2001
Parkinson's Disease, CNS Spectrums	1998

Journal Editorial Boards:

Movement Disorders Journal, Associate Editor	2017 – present
Journal of Parkinsonism and Restless Legs Syndrome	2015 – 2017
Drugs	2013 – present
Journal of Clinical Investigation	2012 – 2017
Current Signal Transduction Therapy	2008 – 2010
Neural Regeneration Research	2007 – 2009

Manuscript Reviewer:

New England Journal of Medicine	2014 – present
JAMA Neurology	2014 – present
Journal of Parkinsonism and Restless Legs Syndrome	2013 – 2017
Tremor Disorders	2012 – present
Annals of Neurology	2008 – present
Lancet Neurology	2008 – present
European Journal of Neurology	2008 – 2016
Journal of Neurology	2008
Progress in Neuro-psychopharmacology and Biological Psychiatry	2008
CNS Spectrums	2008
Aging and Experimental Research	2007
Journal of Neurology Neurosurgery and Psychiatry	2005 – present
Mayo Clinic Proceedings	2005
Human Movement Science	2005
Aging Health	2005
Archives of Disease of Childhood	2005
Gene Reviews	2005
Neuroscience Letters	2005
Archives of Diseases of Childhood	2005
Pharmacy and Therapeutics	2005
Parkinsonism and Related Disorders	2003 – present
Neurology	2003 – present
Clinical Neuropharmacology	2002
CNS Drugs	2002
The Annals of Pharmacotherapy	2002
Southern Medical Journal	1999
Movement Disorders	1997 – present
Neurology Network Commentary	1996

Book Reviews:

Odin P, Hagell P, Shing M. Apomorphine in Parkinson's Disease. Uni-Med Verlag AG. Bremen, Germany. Clin Neuropharmacol 2005

Protocol Steering Committees:

A Phase 2, Open-label, Dose-escalating Study to Evaluate the Safety and Preliminary Efficacy of RTT150 for Injection in Isolated Cervical Dystonia (Chair): Revance Therapeutics	2015 – 2017
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson's Disease Experiencing End of Dose "Wearing-Off": Biotie Pharma	2015 – 2017
An exploratory open-label study of temporary vocal fold augmentation for disordered voice in patients with Parkinson's Disease: Merz Pharmaceuticals	2014 – 2017
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel Group, Dose-ranging Study to Evaluate the Safety and Effectiveness of Arbaclofen Tablets in Multiple Sclerosis Patients with Spasticity: Osmotica	2010 – 2017
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study To Evaluate Effectiveness of Amantadine HCl Extended Release Tablets in Parkinson's Disease Patients with Levodopa-Induced Dyskinesias: Osmotica	2010 – 2017
A 25-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson's disease: Novartis	2010 – 2013
Safinamide in early IPD, as add-on to a single dopamine agonist (MOTION): EMD-Serono	2010 – 2013
A 60-month, double-blind, placebo-controlled, Multicenter Trial of Rasagaline in Parkinson's Disease	2010 – 2011
CERE-120-09, Ceregene	2009 - 2015
A Phase I/II Trial Assessing the Safety and Efficacy of Bilateral Intraputaminial and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease	
A multi-center, double-blind, randomized, parallel-group, placebo-controlled, two-arm safety and efficacy study of nitisinone (SYN118) in patients with Parkinson's disease: Synosia	2008 – 2012
A randomized, double-blind, placebo-controlled parallel-group study to assess the safety and efficacy of SYN115 120 mg/day given in two divided doses for 12 weeks: Synosia	2008 – 2012
<u>C</u> ervical <u>D</u> ystonia <u>P</u> atient <u>R</u> egistry for <u>O</u> bservation of <u>B</u> OTOX [®] <u>E</u> fficacy (CD PROBE): Allergan	2008 – 2015
Treatment of Non-motor Symptoms in Parkinson's disease, Novartis	2008 – 2010
DOMINION: Impulse Control Disorders in Parkinson's disease patients treated with MIRAPEX [®] (pramipexole) and other dopamine agonists, Boehringer-Ingelheim	2006 – 2010
DESTINY: Early Pramipexole Therapy in Parkinson's Disease Boehringer-Ingelheim	2005 – 2009
QUEST-PD, Parkinson Study Group	2004 – 2008
Quality of Life in Parkinson's Disease, Novartis	2004 – 2008
^{99m} Tc-NC100697 SPECT in Parkinson Syndrome, GE/Amersham	2003 – 2016
End of Dose Wearing Off in Parkinson's Disease, Novartis	2001 – 2007
Survey comparison to Physician Evaluation Pilot, Chair	2001 – 2003
COMPASS-1: Survey comparison to Physician Evaluation, Chair	2003 – 2007
Survey validation by Parkinson's Disease experts, Chair	2004 – 2007

Data & Safety Monitoring Committees:

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson's Disease Experiencing End of Dose "Wearing-Off": Biotie Pharma	2015 – 2017
Neurologix, Inc, Chair	2008 – 2012
GAD 2: Phase 2 Safety and Efficacy Study Evaluating Glutamic Acid Decarboxylase Gene Transfer to the Subthalamic Nuclei in Subjects with Advanced Parkinson's Disease	
NPY 1: A Phase 1 Safety Study Evaluating Hippocampal NPY Gene Transfer in Subjects with Intractable Mesial Temporal Lobe Epilepsy	

Data & Safety Monitoring Committees: (continued)

Biogen Idec, LTD: BIIB014 Dose Escalation Study	2007 – 2010
Guilford Pharmaceuticals, Protocol 0501-0201 (GPI-1046)	2003 – 2006

Federal Drug Administration presentation committees:

Chelsea Therapeutics: FDA Advisory Committee Meeting Droxidopa in the treatment of Orthostatic Hypotension	2012
GE Healthcare: FDA Advisory Committee Meeting DaTSCAN as a diagnostic Assessment tool in Parkinson syndrome	2009
Ceregene: National Institutes of Health, Recombinant DNA Advisory Committee (RAC)	2009
Osmotica: Protocol Review Meeting	2008
GE Healthcare: PIND Type C meeting: DaTSCAN as a diagnostic Assessment tool in Parkinson syndrome	2008
Kyowa: Istradefylline as a treatment for Parkinson's Disease	2008
Novartis: Non-motor symptoms of Wearing-off in Parkinson's Disease	2007
GE/Amersham: PIND Type C meeting: ^{99m} Tc-NC100697 SPECT as a diagnostic assessment tool in Parkinson Syndrome	2005

Consulting Activities:

Biorasi	2017
Sunovion Pharmaceuticals	2017
Acadia	2016
BioMarin	2016
Neurocrine	2016
Orient Pharma	2016
Kyowa Kirin	2016
ISCO	2013 – 2015
Acordia	2013
Eli Lilly	2013
Johnson & Johnson	2013
Pfizer	2012 – 2015
SK Life Sciences	2012 – 2014
Merz	2012 – 2015
Neuronova	2011
Chelsea	2012
Noven	2011
Schering-Plough	2009 – 2011
Allergan	2008 – 2015
Synosia/Biotie	2008

Consulting Activities: (continued)	
Biogen-idec	2008 – 2010
Osmotica	2006 – 2016
Vernalis	2006
Boehringer-Ingelheim: DOMINION	2005 – 2009
Ortho-McNeil	2005
Shire Pharmaceuticals	2005
Novartis	2004 – 2010
Endo Pharmaceuticals	2004 – 2006
Amersham/GE Imaging Technologies	2003 – 2010
Kyowa Pharmaceuticals	2003 – 2008
Bertek Pharmaceuticals	2003 – 2005
Medical Community Service:	
WebMD: Expert Commentary, Parkinson's Disease Community	2010 – 2013
Member, Catholic Healthcare West, Mission & Human Resources Committee	2000 – 2001
Physician Advisor, Benign Essential Blepharospasm Research Foundation, Arizona	1997 – 2003
Physician Advisor, Dystonia Medical Research Foundation, Arizona Chapter	1996 – 2003
Physician Advisor, National Parkinson Foundation, Arizona Chapter	1996 – 2003
Staff Neurologist, Boone County Family Health Clinic	1993 – 1996
Physician Advisor, Multiple Sclerosis Institute, University of Missouri	1993 – 1996
Physician Advisor, Dystonia Medical Research Foundation, Mid-Missouri	1993 – 1996
Physician Advisor, American Parkinson's Disease Association, Columbia, MO	1992 – 1996
Physician Advisor, Greater Missouri Tourette Syndrome Chapter	1991 – 1996
Physician Advisory Board, Physician's Home Health & Hospice Network	1993 – 1995
General Community Service:	
Fight Night Foundation Board of Directors	1999 – 2001
Fight Night with Muhammad Ali	1996 – 2002
Missouri Boys State	1979 – present
Board of Trustees	2015 – present
Board of Directors	1993 – present
Dean of Counselors	1993 – 1998
Counseling Staff	1979 – 1999
Teaching responsibilities including continuing education:	
International Presentations:	
National Parkinson Foundation Center of Excellence Leadership Conference Keynote Address	2017
American Academy of Neurology Motor effects and safety of IPX203: A single-dose Phase 2 study	2017
REDCapCon Keynote Address	2016
4 th World Parkinson Congress Impulse Control Disorders in Parkinson's Disease Behavioral Manifestations and Psychosis in Parkinson's Disease	2016
33 rd International Meeting of the Benign Essential Blepharospasm Research Foundation, New Orleans, Future Directions in Blepharospasm	2015
The Expert Conference on Parkinson Disease, Tokyo Nonmotor Symptoms in Parkinson's Disease	2014

International Presentations: (continued)

Patient Satisfaction in the Treatment of Parkinson's Disease, Tokyo Wearing Off Symptoms in Parkinson's Disease	2014
Impulse Control Disorders in Parkinson's Disease, Boston Chair, Organizing Committee Diagnostic Criteria for Impulse Control Disorders in Parkinson's Disease	2012
1 st Annual Dystonia Coalition Meeting, Chicago Session Chair	2012
European Federation of Neurological Societies, Budapest Wearing Off Symptoms in Parkinson's Disease	2011
International Congress of Parkinson's Disease and Movement Disorders, Toronto Wearing Off Symptoms in Parkinson's Disease	2011
7 th International Congress on Mental Dysfunctions & Other Non-Motor Features in Parkinson's Disease: Barcelona Impulse Control Disorders: Clinical Phenomenology Co-Chair: Neurosurgical Treatment in Parkinson's Disease	2010
2 nd World Parkinson Congress, Glasgow Identification of Wearing-off Symptoms in Parkinson's Disease	2010
18 th Symposium Parkinson's Disease and Catecholamine Symposium of Japan Recognition and Treatment of Impulse Control Disorders in Parkinson's Disease	2010
International Congress of Parkinson's Disease, Miami Recognition and Treatment of Impulse Control Disorders in Parkinson's Disease	2009
2 nd Asian and Oceanian Parkinson's Disease and MD Congress; New Delhi, India Medical Management of Advanced Parkinson's Disease Co-Chair: Gait Evaluation and Physical Therapy in Parkinson's Disease	2009
17 th Symposium on the Treatment of Parkinson's Disease. Tokyo Non-Motor Features in Parkinson's Disease	2008
International Congress of Parkinson's Disease and Movement Disorders, Chicago Chair: Impulse Control Disorders in Parkinson's Disease	2008
26 th International Meeting of the Benign Essential Blepharospasm Research Foundation, Minneapolis. Everything you always wanted to know About Blepharospasm, but were afraid to ask	2008
Tokyo Parkinson's Disease Forum Recognition of Wearing Off in Parkinson's Disease	2008
Impulse Control Disorders in Parkinson's Disease, Toronto Chair, Organizing Committee Diagnostic Criteria for Impulse Control Disorders in Parkinson's Disease	2007
25 th International Meeting of the Benign Essential Blepharospasm Research Foundation, Jacksonville. Special Specs for Blepharospasm,	2007
International Congress of Parkinson's Disease and Movement Disorders, Kyoto Etiology and Pathogenesis of Restless Legs Syndrome Impulse Control Disorders in Parkinson's Disease Co-Chair: Sleep Disorders in Parkinson's Disease	2006
Glasgow Parkinson's Disease Forum Improving the Detection of Wearing Off in Parkinson's Disease	2006
Novartis Neuroscience Forum, Malta Recognition of Wearing-off in Parkinson's Disease	2006
World Parkinson Congress, Washington, DC Non-Dopaminergic Drugs in the Pipeline Impulse Dyscontrol Disorders in Parkinson's Disease	2006

International Presentations: (continued)

Royal Academy of Science, London	2005
Treatment of Early Parkinson's Disease	
Thailand Neurological Society:	2005
Annual meeting of Thai Parkinson's Disease and Movement Disorder Club	
Impulse Dyscontrol Disorders in Parkinson's Disease	
Video session: lessons that my patients taught me	
Recognition and Management of Early Wearing-Off Parkinson's Disease	
16th International Congress on Parkinson's Disease, Berlin, Germany	2005
Treatment with Dopamine Agonists	
Behavioral Disorders in Parkinson's Disease	
Parkinson's Disease Symposium, Barcelona, Spain	2005
Co-Chair, Wearing Off Symptoms in Parkinson's Disease	
End of Dose Wearing Off in Parkinson's Disease	
Neurological Assessments in Parkinson's Disease	
9 th International Congress of Parkinson's Disease and Movement Disorders, New Orleans, LA, USA, Apomorphine Rescue Therapy	2005
Poster Highlights Presentation	
Parkinson's Disease Symposium, Tokyo	2005
Sleep Disorders in Parkinson's Disease	
8 th International Congress of Parkinson's Disease and Movement Disorders, Rome	2004
Apomorphine: From: "off" to "on."	
Parkinson's Disease Symposium, Seville	2003
End of Dose Wearing Off in Parkinson's Disease	
20 th International Meeting of the Benign Essential Blepharospasm Research Foundation, Houston. Risk Factors for Blepharospasm,	2002
7 th International Dystonia Patient Symposium and 2 nd Family Symposium, Miami	2002
Talking About Dystonia: panel for children,	
Botulinum Toxin Overview, Medications and Botulinum Toxin,	
Depression and Young Adults: panel	
19 th International meeting of the Benign Essential Blepharospasm Research Foundation, Phoenix. Botulinum Toxin A for Blepharospasm, Meige and Hemifacial Spasm,	2001
18 th International Meeting of the Benign Essential Blepharospasm Research Foundation, Lexington, KY Treatment of Blepharospasm, Meige, & Hemifacial Spasm with Botulinum Toxin B	2000
XLV Reunion annual de la Sociedad Espanola de Neurologia, Barcelona, Spain	1993
Treatment of Motor Fluctuations in the Advanced Parkinson's Disease Patient	

National Presentations and Invited Lectures:

Mo Udall Symposium, Phoenix, AZ	2017
Promising research in Parkinson's Disease 2017	
Michael J Fox Research Symposium, Charlotte, NC	2015
Research Progress in Parkinson's Disease	
Southeast Parkinson Symposium, Spartanberg, NC	2014
Why the Study of Neurological Disease is Important	
National Parkinson Foundation Symposium, Miami	2014
Stem Cells for Parkinson's Disease: Fact or Fiction	
Neurology Update, Miami	2014
Impulse Control Disorders in Parkinson's Disease	
Wearing Off Symptoms in Parkinson's Disease	

National Presentations and Invited Lectures: (continued)

National Parkinson Foundation Symposium, Miami Biomarkers and the Latest Research in Parkinson's Disease	2013
NIH Neuroscience Workshop: Advancing Diagnoses and Treatment of Psychiatric and Neurological Disorders: Moving Functional Imaging Into the Clinic Functional Brain Imaging in Parkinson's Disease: Agency Approval and Community Impact	2013
University of Missouri; Alumni Weekend Impulse Control Disorders in Parkinson's Disease	2012
Mo Udall Symposium, Phoenix Non-Motor Symptoms in Parkinson's Disease	2012
University of Southern California Parkinson's Disease Symposium, Los Angeles A Closer Look at Advanced Parkinson's Disease	2010
New Therapies for Advanced Parkinson's Disease: Surgical Treatments	2010
NIH Sham Neurosurgical Procedures in Clinical Trials for Neurodegenerative Diseases: Neurotrophic Factor Trials for Parkinson's Disease	2010
The Duke Pediatric Neurology Update Course: Demystifying Child Neurology Tourette Syndrome	2009
Parkinson Disease Foundation Learning Institute, New York Parkinson's Disease and Clinical Research	2008
American Academy of Neurology: Evaluation and Treatment of Dystonia, New Orleans Recognition and Treatment Cervical and Limb Dystonia	2008
American Academy of Neurology: Evaluation and Treatment of Dystonia, Gainesville Recognition and Treatment of Blepharospasm Reimbursement Issues with Botulinum Toxin	2007
57 th Annual American Academy of Neurology, San Diego, CA Clinical Therapeutics Course: Parkinson's Disease	2006
NINDS Workshop on Psychosis and Parkinson's Disease Workshop	2005
NINDS Workshop on Advanced Parkinson's Disease Workshop Apomorphine use and potential research opportunities	2005
56 th Annual American Academy of Neurology, San Francisco Treatment of Spasticity and Limb Dystonia	2004
Parkinson Disease of the Carolinas Patient Symposium	2003
Eastern North Carolina Parkinson's Disease Patient Symposium	2003
55 th Annual American Academy of Neurology, Honolulu, HI, USA Treatment of Spasticity and Limb Dystonia	2003
54 th Annual American Academy of Neurology, Denver, CO Practical Management of Movement Disorders Treatment of Spasticity and Limb Dystonia	2002
University of Southern California, Annual Patient Symposium	2001
27 th Annual Barrow Neurological Institute Symposium, Phoenix, AZ Case Presentations: Parkinson's Disease & Related Disorders	2001
National Institute of Health, Database Management of Parkinson's Disease	2001
San Diego Parkinson Association Managing Late Complications of Parkinson's Disease, San Diego, CA	2000
American Academy of Clinical Toxicology/North American Congress of Clinical Toxicology, Tucson. Botulinum Toxin – Another Person's Medicine	2000
26 th Annual Barrow Neurological Institute Symposium, Phoenix, AZ Movement Disorders	2000

National Presentations: (continued)

The Blepharospasm Workshop, National Institute of Neurological Disorders Primary and Secondary Blepharospasm	2000
1999 Mayo Clinic Movement Disorders Course Parkinson's Disease is Not Just a Movement Disorder	1999
25 th Annual Barrow Neurological Institute Symposium, Phoenix, AZ Movement Disorders	1999
Minnesota Parkinson's Disease Patient Symposium	1997
Greater Cincinnati Parkinson's Disease Patient Symposium	1996
47th Annual American Academy of Family Physicians Conference, Irvine, CA Common Neurologic Complaints in a Large Nursing Home Setting,	1995
19th Annual Internal Medicine Conference, Orlando Regional Healthcare System, Orlando, FL, USA. Medical Management of Parkinson's Disease	1995
46th Annual American Academy of Family Physicians Conference, Boston, Massachusetts. Recognition and Treatment of Parkinson's Disease and Other Movement Disorders	1994
44th Annual American Academy of Family Physicians, San Diego, California Treatment of Motor Fluctuations in Moderate to Severe Parkinson's Disease	1992

Accreditation Council Continuing Medical Education Curricula Development:

New Therapies for Advanced Parkinson's Disease; Duke University	2010
The Diagnosis and Treatment of Huntington's Disease; Intellyst	2009
The Management of Parkinson's Disease in the Primary Care Setting; TCL Institute	2009
The Diagnosis and Treatment of Dystonia; Duke CME office	2009
The Diagnosis and Treatment of Dystonia; Duke CME office	2007
Managing Motor Complications in Parkinson's Disease; WE MOVE	2007
Core Curriculum in Movement Disorders; WE MOVE	2007
Dyskinesias: A Clinicians' Guide to Dyskinesia Management in PD; WE MOVE, Chair	2006
The Role of COMT Inhibition in the "Off Time" in Parkinson's Disease; WE MOVE, Chair	2006
PD Workbook: The Clinicians' Guide to Parkinson's Disease; WE MOVE	2006
Apomorphine for the Management of Motor Fluctuations in Parkinson's Disease; MDS	2006
New Horizons in Parkinson's Disease Therapy; AKH/McMahon Publishing Group	2005
CME Cafe: Cooking up Strategies for Movement Disorders and Epilepsy; Intellyst	2005
Improving the Recognition of Wearing Off in Parkinson's Disease; Duke CME office	2005

Grand Rounds/Visiting Professor:**Duke University Medical Center**

2003 – 2017

Kansas University; Pramongkutklo Hospital, Thailand; Taipei Hospital, Taiwan; University of South Alabama/Gulf Coast Neurology Society; Montreal Neurological Institute; Toronto Western Hospital; University of Calgary Hospital; Emory University, Medical University of South Carolina; Eastern Carolina University; Johns Hopkins University; Medical College of Virginia; Georgetown University; Mayo Clinic – Jacksonville; Wake Forest University; University of Minnesota; Phoenix, AZ; Medical College of Georgia; University of Tennessee – Knoxville; University of North Carolina, University of Texas, Southwestern; Ohio State University, Duke University: Department of Neurology (10), Medicine, Geriatric Medicine (2), Duke Clinical Research Institute, Barrow Neurological Institute.

Barrow Neurological Institute 1996 – 2003
 University of Arizona, University of Washington, University of Tennessee – Memphis,
 University of Tennessee – Johnson City, Rush-Presbyterian Hospital, SUNY-Bronx,
 Temple University, Albany Medical College, Duke University Medical Center.

University of Missouri 1991 – 1996
 University of Arkansas, Kansas University, University of Illinois – Peoria, St. Louis
 University, Indiana University, Creighton University, University of California – Irvine,
 University of California – Sacramento, UCLA Veterans Administration Hospital, Louisiana
 State University – Shreveport, University of Oklahoma, University of Chicago, University of
 Illinois, Southern Illinois University, University of Minnesota, Barrow Neurological Institute.

Fellow and Graduate Student Supervision: (Duke University)

Noreen Bukhari, MD PhD; Movement Disorders Fellowship	2017
Anna Bjornsdottir, MD; Movement Disorders Fellowship	2016 – 2017
Ian C. Lee, MD; Movement Disorders Fellowship	2015 – 2016
Deborah Boland, DO; Movement Disorders Fellowship	2012 – 2013
Patrick Hickey, DO; Movement Disorders Fellowship	2010 – 2011
Julia Johnson, MD; Movement Disorders Fellowship	2009 – 2010
Navid Poutaheri, PhD candidate Biomedical Engineering	2008 – 2009
David Sommer, MD; Movement Disorders Fellowship	2008 – 2009
Ariane Park, MD; Movement Disorders Fellowship	2008 – 2009
Andre Snelings, PhD; Post-doctoral mentoring committee	2008 – 2009
Merrill Birdno, PhD; Biomedical Engineering	2006 – 2009
Valerie Street, DO; Movement Disorders Fellowship	2006 – 2007
Sith Sathsornsumetee, MD; Movement Disorders Fellowship	2006 – 2007
Alexis Kuncel, PhD; Biomedical Engineering	2005 – 2007
Rita Tranquilli, DVM, MD; Movement Disorders Fellowship	2004

Fellow and Graduate Student Supervision: (Barrow Neurological Institute)

Frederick de la Vega, MD; Movement Disorders Fellowship	2002 – 2003
Karen Thomas, DO; Movement Disorders Fellowship	2001 – 2002
Padma Mahant, MD; Movement Disorders Fellowship	2000 – 2001
Johan Samanta, MD; Movement Disorders Fellowship	1999 – 2000
Holly Shill, MD; Movement Disorders Fellowship	1999
Kathy Low, PhD; Clinical Psychology	1995 – 1996

Undergraduate Supervision:

Sri Tademeti, Fuqua School of Business, Clinical Research Project	2009
Patrick Lang, Undergraduate Preceptorship	2008 – 2012
Teresa Rice, Undergraduate Preceptorship	2007

Other Mentoring:

Duke University Staff:

Ernst Casimir, Paul James	2017
Amy Nordo, Asba Tasneem, Garland Goins, James Fayson, Mona Malik	2016
Alice Crummel, Jennifer Goins, Yumika Forney, Charique Richardson	2015

Duke University Graduate/Medical:

Kevin Anderson, Dionna Gamble, Monica Gutierrez, Felix Nwogbo, Jasmine Chigbu, Jason Bethea, Sohrab Vatsia, Clay Sherrill, Tara Dalton	2017
Onyemaechi Nwanaji, Ernst Casimir, Srishti Bhagat, Aladine Elsamadicy,	2016

Gabriel Carrillo, Jennifer Creed, Kevin Anderson, Clay Sherrill, Lina Barker, Katelyn Lee, Aaliyah Davy Lindsey Olivere, Jose Lopez	2015
Duke University Faculty:	
Keith Dombrowski, Julie Ann Sosa, Mark Skeen, Lee Hartsell, Tim Collins, Patrick Hickey, Jeff Cooney, Jody Hawes	2017
Keith Dombrowski, Julie Ann Sosa, Julian Yang, Gabi Hanna, Rasheeda Hall, Gentzon Hall, Coleen Cunningham, Greg Palmer, Krista Swisher, Mark Skeen, Lee Hartsell, Tim Collins, Patrick Hickey, Jeff Cooney, Jody Hawes, Jodi Dodds, Theresa Sevilis, Shreyansh Shah	2016
Jody Hawes, Jodi Dodds, Gabi Hanna, Greg Palmer, Christopher Eckstein	2015
Other:	
Loraine Kalia (University of Toronto), Sara Pirio-Richardson (UNM)	2018
Loraine Kalia (University of Toronto), Ihtsham Haq (WFU), Dushyantha Jayaweera (UMiami)	2017
Afreen Allam (SiNON), Dushyantha Jayaweera (UMiami), Noreen Bukhari (Mount Sinai), Ariane Park (OHSU)	2016
Svjetlana Miocinovic (UCSF)	2015
 Institutional Educational Activities:	
Brody School of Medicine:	2017 – present
Neurodegenerative Diseases	
Duke University Medical Center:	2003 – 2017
Chair: Monthly Deep Brain Stimulation Meeting	
Residency Education:	
Pediatric Neurology Conference Lecturer	
Pediatric Movement Disorders	
Hyperkinetic Movement Disorder	
Neurology Conference Lecturer:	
Hyperkinetic Disorders	
Clinical Research in Neurology	
Behavioral Neurology Conference Lecturer	
Medicine Noon Conference Lecturer	
Geriatric Medicine, Morning Conference Lecturer	
Movement Disorders Elective Supervisor	
Movement Disorders Elective Attending (ad hoc for Neurology and Medical/Psychiatry Residents)	
Movement Disorders Geriatric Medicine Fellow Rotation, Supervisor	
Grand Rounds	
Neurology: Parkinson's Disease, Impulse Control Disorders in Parkinson's Disease, Neuroscience Clinical Research at Duke University	
Internal Medicine: Parkinson's Disease	
Geriatric Medicine: Parkinson's Disease	
VA Neurology Clinic Attending: 2003-2005	
Consult Service Attending	
Lecturer: Neurology Elective	
Parkinson's Disease and Movement Disorders	
Lecturer: Clinical Diagnosis	
Neurological Examination	
Lecturer: Psychology 227: Behavioral Physiology	
Movement Disorders	

Lecturer: Physiological Psychology
 Movement Disorders

Lecturer: Biomedical Engineering 265 Neural Prosthetic Systems
 Neurophysiology of Movement

Barrow Neurological Institute:

1996 – 2003

Lecturer: Residency Training Program
 Parkinson's Disease
 Hyperkinetic Movement Disorders

Neurology Grand Rounds:

Parkinson's Disease
 Limb Dystonia and Spasticity
 Dystonia and Botulinum Toxin

Movement Disorders Fellowship Supervisor

Movement Disorders Elective Attending (4 months per year)

Ward Service Attending (1 month per year)

Consult Service Attending (3 months per year)

University of Missouri:

1991 – 1996

Neuroscience II Course Director,

Lecturer: Neurology IV elective

Parkinson's Disease and Movement Disorders

Lecturer: Introduction to Clinical Medicine,
 Neurology Examination

Lecturer: Neuroscience II

Movement Disorders

The Motor System

Functional Anatomy of the Nervous System

The Neurological Examination

Lecturer, Neuroscience I

Case Wrap Up Discussion, The Man with the Shaking Hand

Forgetfulness

Lecture, Department of Medicine Residency Course

Common Movement Disorders in Clinical Medicine

Grand Rounds:

Child Health: Recognition and Treatment of Tic Disorders

Neurology: Parkinson's Disease

Neurology: Huntington's Disease

Neurology: Dystonia

Internal Medicine: Parkinson's Disease

Outpatient Clinic Attending (weekly)

Movement Disorders Elective Attending (4 months per year)

Ward Service Attending (4 months per year)

Consult Service Attending (4 months per year)

Educational Videotapes

DaTSCAN Imaging in Parkinsonian Syndromes and Tremor Disorders

2011

Impulse Control Disorders in Parkinson's Disease: CNN

2008

Wearing off symptoms in Parkinson's Disease

2007

Management of Wearing off in Parkinson's Disease; a panel discussion

2005

Controversies In the Management of Parkinson's Disease

2005

Treatment Strategies in Parkinson's Disease	2004
Insights into the Treatment of Parkinson's Disease	2004
Treatment of Parkinson's Disease	2003
DuPont Pharma, Treatment Strategies in Parkinson's Disease	1992
DuPont Pharma, Insights into the Treatment of Parkinson's Disease	1993
Children's Miracle Network Telethon, Tourette Syndrome	1993

Meetings/Course Director

New Therapies for Advanced Parkinson's Disease	2010
The Use of Botulinum Toxin in the treatment of Dystonia	2006 – 2010
10 th Annual Mo Udall Symposium	2002
19 th International meeting Benign Essential Blepharospasm Research Foundation	2001
9 th Annual Mo Udall Symposium	2001
8 th Annual Mo Udall Symposium	2000
7 th Annual Mo Udall Symposium	1999
6 th Annual Mo Udall Symposium	1998
5 th Annual Mo Udall Symposium	1997
3 rd Annual Missouri/Kansas Parkinson's Disease Symposium	1994

Meetings/Course Director (continued)

Botulinum Toxin in the Treatment of Dystonia and Other Movement Disorders	1994
2 nd Annual Kansas/Missouri Parkinson's Disease Symposium	1994
1 st Annual Missouri/Kansas Parkinson's Disease Symposium	1992
Mid-Missouri Tourette Syndrome Association Meeting	1992
Can We Talk? Tourette Syndrome Meeting	1992

Areas of research interests (basic and applied) - list:

Parkinson's Disease
 Wearing Off Symptoms
 Non-Motor manifestations
 Impulse Control Disorders
 Benign Essential Blepharospasm
 Essential Tremor
 Botulinum Toxin
 Cervical Dystonia
 Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson's Disease
 Genetic Linkage with Parkinson's Disease
 Neurology Clinical Trials

Media Contributions

- [Parkinson's medicine has odd side effect: Gambling: USA Today-Mar 3, 2006](#)
- [New Research to Study if Drugs Can Curb Gambling Addiction: Newsweek-Jun 25, 2008](#)
- [It's Parkinson's, Playaz... Sharon Kha Raps for Awareness: ABC News-Apr 20, 2010](#)
- [Mirror Movement Disorder Forces Limbs to Work in Tandem: ABC News-Apr 29, 2010](#)
- [FDA Approves DaTscan for Imaging of Dopamine Transporters: Medscape-Jan 18, 2011](#)
- [Man Says Parkinson's Drug Made Him Addicted to Gambling and ...: ABC News-Feb 2, 2011](#)
- [Rock Steady Gym Workouts Fight Off Parkinson's Disease: ABC News-Feb 22, 2011](#)
- [Mark Stacy: From Southeast Missouri to international expert: Southeast Missourian-Aug 27, 2011](#)
- [Deep Brain Stimulation May Offer Longer-Term Relief for Parkinson's: U.S. News & World Report-Jun](#)

20, 2012

- [The Placebo Effect: Cough and Other Conditions It Improves: ABC News](#)-Jun 21, 2012
- [Parkinson's Patient Wins Lawsuit Over Gay Sex Addiction: ABC News](#)-Nov 30, 2012
- [Essential Tremor Stilled with Ultrasound Tx: MedPage Today](#)-Aug 14, 2013
- [First drug for Charlotte-based Chelsea Therapeutics wins FDA ...: Charlotte Observer](#)-Feb 25, 2014
- [Results Of Many Clinical Trials Not Being Reported: NPR](#)-Mar 11, 2015
- [Novel Drug Mechanism Addresses Parkinson's Psychosis: Medscape](#)-Jun 29, 2015
- [Advancements in Osmotica's CNS Pipeline for Spasticity in MS ...: Business Wire](#)-Jul 8, 2015
- [Osmotica Announces Its Second Late Stage NDA Asset, OS-320 ...: Business Wire](#)-Jul 22, 2015
- [FDA Accepts New Drug Application for Osmotica Pharmaceutical's ...: Multiple Sclerosis News Today](#)-Oct 1, 2015
- [How Muhammad Ali gave a doctor 'the gift of courage' - CNN.com: CNN](#) Jun 6, 2016
- [How Muhammad Ali Gave a Duke Doctor the Gift of Courage: Duke Today \(blog\)](#)-Jun 6, 2016
- [Reimagining Nursing Research: Accelerating Nursing Science and ...: Duke Today](#)-Aug 10, 2016
- [The Casino Trap: AARP News](#)-Oct 4, 2016

External support - gifts, grants, and contracts:

Federal and Foundation Grants - Past:

- 1Ro1NS058949-01A1 A Brashear (PI) NINDS: Clinical, Genetic, and Cellular Consequences of Mutations in Na, K-ATP1A3, Sub-Investigator 2008- 2017
- 5R21 NS055320 02 W Grill (PI) NIH: Selective Electrical Stimulation of Thalamic Neurons Role: Sub-Investigator 2006- 2017
- 5U01 NS044453 05 Burton Scott, PhD, MD. A Multicenter, Double-Blind, Futility Study of Minocycline and Creatine in subjects with early untreated Parkinson's Disease. Role: Co-Investigator. National Parkinson Foundation Center of Excellence Grant- Duke Movement Disorders Center, Durham, NC 2009-Current \$60,000.
- 5U01 NS044453 05 Burton Scott, PhD, MD. A Multicenter, Double-Blind, Futility Study of Minocycline and Creatine in subjects with early untreated Parkinson's Disease. Role: Co-Invest
- Michael J. Fox Foundation for Parkinson's Research: Validation of Dyskenesia Rating Scales: Proposal Submission to MJFF , 2010- current
- 1 U13 NS59293-1 M Stacy (PI). NINDS: Impulse Control Disorders in Parkinson's Disease Workshop: 4/1/07 – 3/31/08.
- 1 P50 NS39764-1 JM Vance (PI). NINDS /Clinical Core Co-PI: The Genetics of Parkinsonism. Morris K. Udall Parkinson's Disease Research Center of Excellence. 9/30/99 – 3/31/07. 10% salary support.
- 7RO1 NS040894 W Grill. Selective Electrical Stimulation of Thalamic Neurons. 9/1/00-8/31/05. 5% salary support.
- Michael J Fox Foundation: C. Goetz (PI) "Topiramate as an adjunct to amantadine in the treatment of dyskinesia in Parkinson's disease"
- Michael J Fox Foundation. Placebo response in Parkinson's Disease:
- National Parkinson Foundation Center of Excellence Grant, Duke University: 2009; \$60,000
- American Parkinson's Disease Foundation, Information and Referral Center Grant: Duke University: 2003-2005: \$60,000
- National Parkinson Foundation Center of Excellence Grant, Phoenix, AZ: 1996-2003: \$750,000
- Muhammad Ali Parkinson Research Center Grant, Barrow Neurological Foundation, 2002-2003: \$459,393
- Muhammad Ali Parkinson Research Center Grant, Barrow Neurological Foundation, 2001-2002: \$147,865
- "The Ali Project," Barrow Neurological Foundation, 2001-2002: \$433,680
- Muhammad Ali Parkinson Research Center Grant, Barrow Neurological Foundation, 2000-2001: \$105,000
- Muhammad Ali Parkinson Research Center Grant, Barrow Neurological Foundation, 1999-2000: \$110,000

Research Contracts:**Past:**

- Assessment of the Effect of Treatment Pathways, Adherence and Treatment Efficacy in Parkinson's Disease Subjects Randomized to SPECT Imaging of the Dopamine Transporter" GE Healthcare Inc. 2011- 2017.
- A Phase 2, 12 Week, Double-Blind, Dose-Finding, Placebo Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses (1 mg, 2 mg BID, 5 mg BID) and Possibly 10 mg BID) in Subjects with Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias Protocol: PO4501. Sponsor: Schering Plough Research Institute, 2007 – 2017.
- A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE- 120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease Protocol: Cere-120-09 Sponsor: Ceregene, Inc., 2009 – 2017
- A Study to Evaluate the Safety and Efficacy of IPX066 in Advanced Parkinson's Disease Protocol: IPX066-B09-02. Sponsor: Impax Pharmaceuticals, 2010 – 2017
- Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Safety, Tolerability, and Efficacy Study of NP002 in Subjects with Idiopathic Parkinson's Disease with Dyskinesias Due to Levodopa Therapy Protocol: NP002-09-001. Sponsor: Neurraltus Pharmaceuticals, Inc., 2010- 2017
- A phase III, double-blind, placebo-controlled randomized trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson's Disease treated with a stable dose of a single dopamine agonist. Protocol: MOTION (27918) Sponsor: EMD Serono, Inc., 2010 – 2015
- A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson's disease (PD) and cognitive impairment. Protocol: EMR 701165-024 Sponsor: EMD Serono, Inc., 2011 - 2015
- Prospective, double-blind, placebo-controlled, randomized, multi-center trial with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of blepharospasm. Sponsor: Merz Pharmaceuticals, 2007 – 2009.
- Multicenter, Randomized, Double-Blind, Sham Surgery-Controlled Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) to Assess the Efficacy and Safety of Bilateral Intraputaminal (IPu) Delivery in Subjects with Idiopathic Parkinson's Disease. Sponsor: Ceregene, Inc. 2007- 2010
- A prospective, multi-center, randomized, open-label study with blinded raters to evaluate the effects of immediate versus delayed switch to Stalevo® on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off. Sponsor: Novartis (PI), 2006 – 2008
- A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of **Stalevo™** in patients with Parkinson's disease requiring initiation of levodopa therapy STRIDE-PD: ELC200/Stalevo™ Sponsor: Novartis, 2005 – 2008.
- A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects TVP-1012/500 (ADAGIO). Sponsor: Teva Pharmaceuticals (Co-Investigator), 2006 – 2008.
- Safety and Efficacy of Melperone in the Treatment of Patients with Psychosis Associated with Parkinson's Disease. Sponsor: Ovation Pharmaceuticals (PI), 2006 –2007.
- Evaluation of the Efficacy and Safety of ALTROPANE for Differentiating Parkinsonian Syndromes from Non-Parkinsonian Syndromes in Patients with Tremors. Sponsor: Boston Life Sciences (Co-Investigator) 2005-2006
- A double-blind, placebo-controlled, multicenter, multinational study (phase III) to evaluate the safety and efficacy of **Sarizotan** in patients with Parkinson's disease suffering from L-dopa-induced dyskinesia. Sponsor: Merck KgaA 2005-2006.
- Investigating the effects of short-term with pramipexole or levodopa on [123I]b-CIT and SPECT imaging in early Parkinson's disease. Sponsor: Institute for Neurodegenerative Disease, 2005 – 2006.

- Study Group and Cephalon, Inc. Co-Investigator: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients with Early Parkinson's Disease, 2002-2006.
- GlaxoSmithKline, Co-Investigator: A Randomized, Double Blind, Three Period, Cross-Over Study of Ropinirole CR and Ropinirole IR Mono-Therapy in Subjects with Early Phase Parkinson's Disease, 2003 – 2005
- NPDCS (NINDS PD Cooperative Studies), Co-Investigator: A Multicenter, Double-Blind, Futility Study of Minocycline and Creatine in subjects with early untreated Parkinson's Disease. 2003 – 2005.
- Amgen Inc. Co-Investigator: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Liaternin (r-metHuGDNF) Administered by Bilateral Intraputaminial (IPu) Infusion to Subjects with Idiopathic Parkinson's Disease, 2003 – 2005.
- GlaxoSmithKline, Principle Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Six Months Treatment with Ropinirole CR as Adjunctive Therapy in Patients with Parkinson's Disease who are not optimally controlled on L-Dopa, 2003 – 2005.
- Elan Pharmaceuticals, Inc. Co-Investigator: An Open-Label Safety and Immunogenicity Study of Myobloc™ (Neurobloc®, Botulinum Toxin Type B) Injectable Solution in Patients with Cervical Dystonia, 2001-2005.
- Ipsen, Ltd. Principle Investigator: A Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled study to Assess the Efficacy and Safety of a Single Treatment by Subcutaneous Injection, of 3 doses of DYSPORT for injection (40 units/eye, 80 units/eye and 120 units/eye) for the Treatment of Bilateral Blepharospasm, 2002-2003.
- Kyowa Pharmaceutical, Inc. Principle Investigator: A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of Doses of 20 and 60 mg/day KW-6002 as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy (US-006), 2002-2003
- Kyowa Pharmaceutical, Inc. Principle Investigator: A Long-Term, Multicenter, Open-Label, Safety Study with a Flexible Dose Range of KW-6002 as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy (US-007), 2002-2003.
- Novartis Pharmaceuticals. Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, dose-ranging, efficacy and safety study of three doses of TCH346 (0.5 mg, 2.5 mg and 10 mg daily) in patients with early Parkinson's Disease, 2002-2003.
- Elan Pharmaceuticals, Inc. Principal Investigator: An Open Label Study of Botulinum Toxin Type B (MYOBLOC) in Patients with Benign Essential Blepharospasm, 2002-2003
- Schwarz Biosciences. Principle Investigator: A Multicenter, Multinational, Phase III, Randomized, Double-blind, Parallel group, Placebo-controlled Trial of the Efficacy and Safety of Rotigotine, CDS Patch (2 target doses) in Subjects with Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa, 2002-2003.
- Schwarz Biosciences. Principle Investigator: A Multicenter, Multinational, Phase III, Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of the Rotigotine CDS Patch in Subjects with Early Stage Idiopathic Parkinson's Disease, 2002-2003.
- Ortho-McNeil Pharmaceutical, Inc. Principle Investigator: A Comparison of the Efficacy and Safety of Topiramate versus Placebo in the Treatment of Essential Tremor, 2001—2003.
- Baylor College of Medicine. Principle Investigator: Botulinum Toxin Type B Observational Study, 2001-2003.
- Elan Pharmaceuticals, Inc. Principle Investigator: An Open-Label Safety and Immunogenicity Study of Myobloc™ (Neurobloc®, Botulinum Toxin Type B) Injectable Solution in Patients with Cervical Dystonia, 2001-2003.
- Dystonia Study Group and Rush Presbyterian St. Luke's Medical Center. Principle Investigator: A Randomized, Multicenter, Double Blind, Parallel Group Study Comparing Botox® (Botulinum Toxin Type A) and Myobloc™ (Botulinum Toxin Type B) in Cervical Dystonia (CD) Subjects Responsive to Botulinum Toxin Type A, 2001-2003.
- Parkinson Study Group and TEVA Pharmaceuticals, USA. Sub-Investigator: A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in

- Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy, 2001-2003.
- Ortho-McNeil Pharmaceuticals, Inc. Principal Investigator: CAPSS-149: Video Tape Recording of Tremor Evaluation & Tremor Rating Scale in Subjects with Essential Tremor, February 2001.
- Allergan. Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel Group Study of the Continuation of Benefit of Two Dosages of BOTOX Purified Neurotoxin Complex for the Prophylactic Treatment of Migraine Headaches, 2000.
- Amgen, Inc. Principal Investigator: Randomized, Double-blind, Placebo-controlled, Parallel-group, 6-month Safety, Efficacy and Neuroimaging Trial of AMG-474-00 in the Treatment of Parkinson's Disease 2000-2002.
- Novartis Pharmaceuticals. Sub-Investigator: A Multicenter, Double-blind, Placebo-Controlled Study of the Tolerability and Effect of Entacapone in Parkinson's Subjects with End-of-dose Wearing-off Symptoms Occurring no Earlier than 4 Hours after their Most Recent Levodopa/Carbidopa Dose. 2000-2003.
- Parkinson Study Group and TEVA Pharmaceuticals, USA. Principal Investigator: A Bi-national, Multicenter, Open-label Study to Evaluate the Safety and Tolerability of TV-1203/Carbidopa Dispersible Tablets in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy 2000-2003.
- Parkinson Study Group and TEVA Pharmaceuticals, USA. Principal Investigator: Randomized, Double-Blind, Double Dummy, Parallel Group Study Comparing TV-1203/Carbidopa Dispersible Tablets with Levodopa/Carbidopa Tablets in Advanced Parkinson's Disease Patients 2000-2003.
- Parkinson Study Group and TEVA Pharmaceuticals, USA. Sub-Investigator: Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study for the Efficacy, Tolerability, and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson's Disease Patients, 2000-2003.
- Pharmacia & Upjohn. Principal Investigator: PNU-95666E/0011: Open-label, Long Term, Flexible Dose Study of Safety, Tolerability, and Therapeutic Response in Patients with Parkinson's Disease, 2000-2003.
- Pharmacia & Upjohn. Principal Investigator: PNU-95666E/0009: Double-blind, Placebo-controlled, Dose-Response Study of Tolerability, Safety, and Efficacy in Patients with Early Parkinson's Disease, 2000-2003.
- Parkinson Study Group and Schwarz-Pharma. Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Escalating Transdermal Doses of SPM 962 in Subjects with Early Parkinson's Disease, 2000.
- Roberts Pharmaceuticals. Principal Investigator: Midodrine in the Treatment of Parkinson's Disease, 1999. Co-Principal Investigator: Deep Brain Stimulation of the Subthalamic Nucleus for the Treatment of Parkinson's Disease, 1999-2003.
- Allergan. Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Three Dosages of Botox (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Prophylactic Treatment of Migraine Headache, 1999-2000.
- TEVA Pharmaceuticals, USA. Principal Investigator: A Multicenter, Open-Label, Phase III Study for the Safety, Tolerability and Clinical Effect of Rasagiline Mesylate in Patients with Parkinson's Disease, 1999-2003.
- Pharmacia & Upjohn. Principal Investigator: The Effect of Pramipexole on Depressive Symptoms in Parkinson's Disease Patients, 1999-2000.
- Pentech Pharmaceuticals, Inc. Principal Investigator: Open-label, Compassionate Use Assessment of the Safety of Apomorphine Hydrochloride Sublingual Tablet as Adjunct Treatment for Motor Fluctuation ("On/Off") Occurrence in Late-Stage Parkinson's Disease, 1999-2000.
- Pentech Pharmaceuticals, Inc. Principal Investigator: Placebo-Controlled, Double-Blind Study of the Safety and Efficacy of Apomorphine HCl Sublingual Tablets as Adjunct Treatment for Motor Fluctuation ("On/Off") Occurrence in Late-Stage Parkinson's Disease, 1999-2000.
- Parkinson Study Group and TEVA Pharmaceuticals, USA. Principal Investigator: A Multicenter, Double-Blind, Parallel Group, Phase III Study for the Efficacy, Tolerability, and Safety of Rasagiline Mesylate in Early

- Parkinson's Disease Patients Not Treated with Levodopa, 1998-2000.
- Parkinson Study Group, Pharmacia & Upjohn. Principal Investigator: Comparison of the Agonist Pramipexole vs. Carbidopa-Levodopa on Motor Complications of Parkinson's Disease, 1998--2003.
- Parkinson Study Group and Columbia University. Principal Investigator: Earlier vs. Later Levodopa in Parkinson's Disease, 1998-2003.
- National Institutes of Health and Boston University, Principal Investigator, Genetic Linkage with Parkinson's Disease, 1998-2003.
- Parkinson Study Group and Indiana University School of Medicine. Principal Investigator: Parkinson Disease Collaborative Study of Genetic Linkage, 1998-2003.
- Eli Lilly and Company. Principal Investigator: Olanzapine vs. Placebo for Treatment-Associated Psychosis in Patients with Parkinson's Disease, 1998-1999.
- Amgen Inc. and Medtronic, Inc. Principal Investigator: GDNF 970195: Open-label, Within-patient, Dose-escalation Trial of Intracerebroventricular recombinant-methionyl Human Glial Cell Line-derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Patients with Idiopathic Parkinson's Disease, 1998-1999.
- Amgen Inc. and Medtronic, Inc. Principal Investigator: GDNF 960173: Open-label Trial of Intracerebroventricular recombinant-methionyl Human Glial Cell Line-derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Patients with Idiopathic Parkinson's Disease, 1998-1999.
- Amgen Inc. and Medtronic, Inc. Principal Investigator: GDNF 960103: Randomized, Double-blind, Placebo-controlled, Dose-escalation Trial of Intracerebroventricular recombinant- methionyl Human Glial Cell Line-derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Patients with Idiopathic Parkinson's Disease, 1998-1999.
- SmithKline Beecham and University of South Florida. Principal Investigator: Pramipexole-Ropinirole Switching Study in Advanced Parkinson's Disease Patients on Levodopa, 1998-2000.
- Parkinson Study Group and Sibia Neurosciences, Inc. Principal Investigator: A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study for the Safety, Tolerability and Efficacy of SIB-1508Y in Parkinson's Disease Patients who are Requiring but Not Receiving Dopaminergic Therapy, 1998-1999.
- MDS Harris and Scherer DDS. Principal Investigator: An Open Extension of the Safety and Efficacy of Zydis Selegiline 1.25 to 2.5mg Q.D. as an Adjunct in the Management of Parkinson's Patients Being Treated with Levodopa (Zydis 027), 1998.
- Parkinson Study Group and Astra Merck, Inc. Principal Investigator: A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study for the Safety, Tolerability and Efficacy of Daily, Oral Doses of Remacemide Hydrochloride in Parkinson's Disease Subjects with Motor Fluctuations, 1998.
- Parkinson Study Group and Astra Merck, Inc. Principal Investigator: A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study for the Safety, Tolerability and Efficacy of Daily, Oral Doses of Remacemide Hydrochloride in Subjects with Early Parkinson's Disease, 1998.
- Parkinson Study Group. Principal Investigator: Rasagiline Mesylate (TVP-1012) in Early Monotherapy for Parkinson's Disease Outpatients, 1997 -1998
- MDS Harris and Scherer DDS, Co- Investigator, A Randomized, Double-Blind, Parallel-Group Study to Compare the Safety and Efficacy of Zydis Selegiline 1.25mg to 2.5mg QD with Placebo as an Adjunct in the Management of Parkinsonian Patients Being Treated with Levodopa Who Exhibit Deterioration in the Quality of Their Response to Therapy, 1997.
- MDS Harris and Scherer DDS, Principal Investigator, An Open Multicenter Parallel-Group Continuation Study to Compare the Safety of 1.25mg to 10mg QD Zydis Selegiline in Control of the Symptoms of Parkinson's Disease in Patients Stabilized on a Regimen Including Selegiline, 1997.
- Parkinson Study Group, Principal Investigator, A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Remacemide in the Treatment of the Early Parkinson's Disease Patient, 1997.
- Novartis Pharmaceuticals, Investigator, A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Entacapone in the Stable Parkinson's Disease Patient, 1997.
- Pharmacia, Principal Investigator, A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of

Cabergoline in the Treatment of Parkinson's Disease, 1995 –1996.
Allergan, Inc., Principal Investigator, A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Intramuscular BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Cervical Dystonia, 1995 –1996.
Pharmacia, Inc., Principal Investigator, Cabergoline in the Treatment of Parkinson's Disease: Long-Term Use, 1995 –1996.
Berlex Pharmaceuticals, Principal Investigator, Beta-Interferon in the Treatment of Multiple Sclerosis: A Continuing Open-Label Trial, 1994.
Sandoz Pharmaceuticals, Principal Investigator, Efficacy of Clozapine in the Treatment of Tardive Dyskinesia in Long-Term Schizophrenia, 1993.
Pfizer Pharmaceuticals, Principal Investigator, Efficacy of Sertraline in the Treatment of Tourette Syndrome, 1993.

Participation in academic and administrative activities of the University and Medical Center:

Dean, School of Medicine

- Offices reporting to Dean, School of Medicine
 - Vice Dean for Operations
 - Senior Associate Dean for Academic Affairs
 - Associate Dean for Research
 - Associate Dean for Diversity and Inclusion
 - Associate Dean for Faculty and Development
 - Executive Director, ECU Physicians
 - Department Chairs, ECU School of Medicine

Personal Information

Faculty member's preferred familiar name: Mark Stacy, MD.

Local home address:

775 Lexington Drive
Greenville, NC 27834

Cell Phone # (919)-451-9183

Marital status: Married

Name of spouse: Tina Estrada Stacy, PhD